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Aims 
 
   The aims of this thesis were to explore strategies to treat FN patients effectively 
and safely while simultaneously contributing to avoid development and spread of 
unnecessary antibiotic resistance.  
   In Norway, there has been a long medical tradition to treat severe infections, 
including FN, with penicillin G plus an aminoglycoside. There are reasons to assume 
that this regimen causes less antibiotic resistance than indiscriminate use of broad-
spectrum antibiotics. 
 
To achieve the overall objectives, we decided to focus on three main topics: 
 
1. To summarize the evidence in the medical literature for the efficacy and safety of 
penicillin G plus an aminoglycoside in the initial treatment of FN. 
 
2. To conduct a randomized, controlled trial to evaluate if tobramycin administered 
once daily was as effective as tobramycin administrated three times daily, both given 
with penicillin G, as initial empiric therapy in FN cancer patients. 
 
3. To map the inflammatory response in FN patients and to explore if inflammatory 
markers of patients with newly developed FN were sensitive and specific enough to 
characterize and predict the severity and the clinical outcome of the FN episode as 
aid in deciding the antibiotic treatment. 
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1. Introduction 
 
   Febrile neutropenia (FN) has been one of the major challenges in oncology and 
hematology since modern anticancer chemotherapy became standard of care  
[Silver, et al., 1958; Boggs and Frei, III, 1960]. Prior to 1961, less than 10 % of 
patients with serious underlying diseases survived an episode of pseudomonas 
septicemia [Bodey, et al., 1973]. “In a classic study of Gram-negative bacillary 
bacteraemia, McCabe and Jackson [McCabe and Jackson, 1962] reported a 90 % 
mortality rate in patients with rapidly fatal underlying illnesses, most of whom had 
neutropenia and cancer” [Klastersky, 1993]. The oncological and hematological 
communities soon saw the need for systematic research to develop the medical field 
of FN patient management, one of the most important complications of modern 
cancer chemotherapy, a condition responsible for a major share of the fatalities and 
morbidities in cancer patients in the Western World.  
   In Europe, The European Organization for Research and Treatment of Cancer 
(EORTC) was established in Belgium in 1962, and the branch called the International 
Antimicrobial Therapy Cooperative Group (IATCG) was founded in 1973 ”…with a 
protocol designed to investigate the optimal initial antimicrobial therapy for FN 
patients with malignant diseases. Before this time, the outcome of sepsis in 
granulocytopenic cancer patients had been dismal” [Klastersky, 1993].  
   Major improvements in therapy of FN and clinical and epidemiological knowledge 
about the condition were gained through the many studies that followed. Four major 
randomized and controlled trials (RCT) had established a standard of care at the 
beginning of the 1990s, and one of the most important leaders of these trials, 
professor Jean Klastersky, summarized the findings in an important review from 1993 
[Klastersky, 1993]. He concluded that an anti-pseudomonal ȕ-lactam and an 
aminoglycoside should be started empirically as soon as possible when a new FN 
episode developed, “…especially in patients with severe and persistent 
granulocytopenia who have suspected or demonstrated Gram-negative bacillary 
bacteraemia.” 
   Further studies established monotherapy with a broad-spectrum ȕ-lactam antibiotic 
as standard therapy in FN in many countries [Paul, et al., 2003; Klastersky, 2009; 
Paul, et al., 2010]. The 2010 Cochrane Collaboration metaanalysis, based on 68 
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RCTs, concluded that a broad-spectrum ȕ-lactam with addition of an aminoglycoside, 
compared to monotherapy with a broad-spectrum ȕ-lactam, showed a trend toward 
all-cause higher mortality (RR 0.87, 95 % confidence interval (CI): 0.75 to 1.02), and 
more adverse events “…with combination therapy, numbers needed to harm four  
(95 % CI: 4 to 5). Specifically, the difference with regard to nephrotoxicity was highly 
significant” [Paul, et al., 2010]. But “nearly all trials were open-labeled”, and no 
evaluation of antibiotic resistance development were done in these RCTs.  
So, even if the arguments for broad-spectrum monotherapy may be strong, we shall 
see that this issue is more complicated. 
   Klastersky [1993] pointed out that aminoglycoside monotherapy was dismal in FN, 
but aminoglycosides prevented both the development of ȕ-lactam resistance and at 
the same time enhanced the efficacy of the ȕ-lactam through synergy or additive 
effects [Amsterdam, 1996]. The issue of aminoglycoside protection against 
resistance development against ȕ-lactams is complicated and has never been fully 
elucidated [Gribble, et al., 1983].  
   This thesis argues that the combination of penicillin G plus an aminoglycoside is 
both safe and efficient in many cases of FN, and that the addition of an 
aminoglycoside to a ȕ-lactam regimen may protect the ȕ-lactam against development 
of resistance [Gilbert and Leggett, 2010]. 
   There are reasons to assume that the combination of penicillin G plus an 
aminoglycoside may confer important synergistic or additive effects to each other and 
is different from aminoglycoside monotherapy; as discussed by Klastersky [1993]. It 
was said that sensitivity to both antibiotics was needed, but in vitro studies have 
documented that synergy may have important implications even when the bacterial 
isolate was resistant toward both the aminoglycoside and the ȕ-lactam. Already in 
1969 an in vitro study [Sonne and Jawetz, 1969] showed synergistic effects between 
ȕ-lactams and aminoglycosides in some strains of Pseudomonas aeruginosa that 
were inhibited, but not killed, by carbencillin. The Gram-negative bacilli showed up to 
10-fold decrease in the minimum inhibitory concentration (MIC) when a small 
concentration of gentamicin (from < 0.125 to 1.0 mg/L) was present. In combination, 
all the bacteria were killed within 24 hours; compared to when the antibiotics were 
tested singly. Then the bacteria continued to grow. Similar results were found in an 
animal study by Lumish and Norden [Lumish and Norden, 1976].  
   An in vitro study of P. aeruginosa [Song, et al., 2003] documented synergy in most 
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isolates that singly were resistant to both drugs tested when the drugs were ȕ-
lactams and aminoglycosides. Applied to clinical situations, the increased sensitivity 
in resistant isolates promoted by synergy or additive effects may be important 
[Andriole, 1971; Klastersky and Zinner, 1982].  
   This is important as a background for the results of our study “Tobramycin once 
versus three times daily, given with penicillin G, to febrile neutropenic cancer patients 
in Norway: a prospective, randomized, multicentre trial” for short called The 
Tobramycin Trial. When we take into account the fact that important Gram-negative 
bacilli such as wild-type Escherichia coli have minimal inhibitory concentration (MIC) 
values toward penicillin G of 34 - 64 mg/L [Kucers, et al., 1997], the penicillin serum 
concentrations may be sufficient to exert an antibacterial effect against E. coli when 
an aminoglycoside works in combination with penicillin G. 
   Another example of Gram-negative bacilli with penicillin G MIC values that may be 
overcome by the combination of penicillin G and an aminoglycoside was a study with 
a wild type E. coli with an MIC value toward penicillin G of 32 mg/L, and a Proteus
mirabilis with an MIC value of 16 mg/L toward penicillin G [Livermore and Williams, 
1996]. Livermore and Williams did not study neutropenic patients. However, they 
showed that penicillin G may have antibacterial effect against some Gram-negative 
bacilli. Neutropenic patients need higher antibiotic concentrations and more effective 
antibiotic therapy than immunocompetent patients. Still, the results from The 
Tobramycin Trial suggested that high doses of penicillin G administered with an 
aminoglycoside toward which the bacteria were sensitive, might have killed these 
bacteria with the help of the synergy between the two antibiotics. 
   Penicillin G has a protein-binding of 55 % and a half-life of 30 minutes. One million 
units give a mean serum concentration of 9.9 mg/L (range 4.3 to 17.5) after one hour 
[Bamberger, et al., 2005]. The concentrations vary according to the different body 
fluids, with highest concentration in bile (mean 45.7; range 2.2 to 189 after one hour) 
where it is excreted. The penicillin G dose in our study was 5 million units. Thus, 
penicillin G probably participated in the bacterial killing of the Gram-negative bacilli, 
but the importance of high aminoglycoside concentrations must be underlined for the 
effective bacterial killing. 
   Resistance to penicillin G in Gram-negative bacilli is often based on ȕ-lactamase 
production and problems with penetrance and efflux [Kucers, et al., 1997]. In the cell 
wall of the bacteria penicillin and other ȕ-lactam antibiotics bind covalently to 
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transpeptidases (penicillin-binding proteins) of which there are several different kinds. 
The transpeptidases cross link the peptidoglycan strands which constitute an 
important part of the bacterial cell wall. This cell wall is the exoskeleton of the 
bacterium and thereby supports the high intracellular osmotic pressure necessary for 
the survival of the bacterium. Inhibition of peptidoglycan production effectively breaks 
down the cell wall in growing bacteria; and this is a main antibacterial mechanism of 
the ȕ-lactam antibiotics. However, only actively growing and dividing bacteria 
produce peptidoglycan [Chambers, 2010]. But this is exactly the situation in bacterial 
sepsis with bacteria growing in the blood, the most important situation we try to fight 
in FN. 
   In Norway, the regimen of penicillin G plus an aminoglycoside has remained the 
standard of care as initial empiric therapy in FN as well as in community-acquired 
sepsis of unknown origin. The Norwegian human microbiological epidemiology, as 
well as the antibiotic consumption, has been monitored since year 2000 by the 
government financed NORM/NORM VET program [Nyquist, 2000]. NORM/NORM 
VET presents their national results in annual reports of antimicrobial resistance and 
antibiotic consumption both in human and veterinary medicine, as well as in 
agriculture and aquaculture. The last published report [NORM/NORM VET, 2011] 
presented the results from 2011. This document confirmed the general low rate of 
resistance and the prevailing use of narrow-spectrum antibiotics in Norway, giving an 
epidemiological support for continued use of penicillin G plus an aminoglycoside in 
FN and other septic infections.  
   The ȕ-lactam coverage of penicillin G is substantially narrower than the anti-
pseudomonal ȕ-lactam recommended by Klastersky in 1993. According to the 
NORM/NORMVET 2011 report, analyzing isolates from blood cultures, with the 
addition of isolates from cerebrospinal fluids for Streptococcus pneumonia, penicillin 
G monotherapy would cover most streptococci (S. pneumoniae was analyzed and 96 
% of the isolates were sensitive to penicillin), and 70 % of the enterococci would be 
covered by ampicillin among the main pathogens. Still, the key to the success of The 
Tobramycin Trial seems to have been the synergy and the additive effects of 
penicillin G plus an aminoglycoside. 
   If this regimen is efficient and safe in severe infections, including bacteremia with 
Gram-negative bacilli, the primary choice of penicillin G plus an aminoglycoside in FN 
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and in sepsis of unknown origin may be an important contribution to prevent the 
development, selection and spread of antibiotic resistance. 
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2. The scientific background of the Tobramycin Trial 
 
2.1 The four major EORTC trials on febrile neutropenia 
 
   These four open-labeled RCTs aimed at defining the optimal antibiotic regimen in 
FN cancer patients, based on the available antibiotics at the time (1975 to 1990). A 
second benefit of these trials was the establishment of the clinical epidemiology of 
FN. The focus was on classifying the febrile episodes and defining other prognostic 
factors, with regard to clinical outcome and microbiological findings, especially 
bacteremias. The total number of FN episodes evaluated for participation in the four 
trials varied from 625 in the first trial to 1074 in the fourth trial. Sixty-six to 79 % of the 
patients had leukemia or lymphoma.  
   In the first trial, responses were defined as “…(1) improvement if there was a 
lasting return of temperature to normal or the level before infection and resolution of 
all signs and symptoms without addition of other antibiotics, (2) temporary 
improvement if there was improvement in (1) but relapse occurred within five to 
seven days, (3) failure if there was no or minimal response to antibiotics or if 
antibiotics required changes or additions, or (4) not evaluable if the patient had viral 
or fungal infection, a protocol violation had occurred, or the episode was classified as 
a doubtful infection” [Klastersky, et al., 1978].  
   This definition of response was only modified to minor degrees in the following 
three trials. When “not evaluable” episodes were excluded, evaluable episodes 
ranged from 50 to 81 % of the total number of FN episodes in trial two, three and four 
(trial one did not report the number of non-evaluable episodes). The number of 
patients with bacteremia ranged from 13 to 29 % of the evaluable patients. The 
number of episodes with renal dysfunction was in general low (3 - 7 %), with no 
difference in toxicity between any of the antibiotic regimens; except for the 
cephalothin plus gentamicin arm in the first EORTC trial, where 16 % of the episodes 
developed renal dysfunction [Klastersky, et al., 1978].  
   This nephrotoxic effect of cephalosporins applies only to some cephalosporins in 
combination with an aminoglycoside; but the specific mechanism has still to be 
elucidated [Luft, 1982]. 
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   The first EORTC trial [Klastersky, et al., 1978] compared three antimicrobial 
regimens. It was based on the preceding work by Schimpff [Schimpff, et al., 1971]. 
The antipseudomonal penicillin, carbencillin, plus gentamicin, were found to be the 
superior regimen, compared to carbencillin plus cephalothin and cephalothin plus 
gentamicin. This trial also established the basic epidemiology of FN. Approximately 
40 % of the patients had a microbiological cause for their FN. Twenty-two percent of 
the patients (140 of 625) had bacteremia. The response to empirical antimicrobial 
therapy was almost similar in patients with increasing granulocytes, whether the 
isolate was sensitive to both (50 % of the isolates) or only to one of the antibiotics  
(43 % of the isolates). Improvement was registered in 58 % of the episodes with 
bacteremia sensitive to both antibiotics, and in 47 % of the episodes sensitive to only 
one of the antibiotics. Response rates were better for Gram-positive bacteremias  
(72 %) than for Gram-negative bacteremias (56 %). Fatality rate was higher in mixed 
Gram-negative bacteremias (63 %) than in single Gram-negative bacteremias  
(25 %). Of the total 20 candida infections, seven were candidemias. Use of 
corticosteroids increased the risk of infection with candida (55 %; 11 infections in 20 
patients); however, the cancer diagnosis of acute lymphocytic leukemia had a five-
fold increase in candida infection (12 %; 7 infections in 60 patients) compared to 
acute myelocytic leukemia (2 %; 6 infections in 310 patients) and other cancers  
(3 %; 7 infections in 255 patients). 
   “However, when all of the prognostic factors were considered together, change in 
granulocyte count during therapy became the critical factor provided that the patient 
had been given antibiotics to which the organism was susceptible” [Klastersky, et al., 
1978]. 
   This first trial raised the question of the role of aminoglycosides in FN. 
Aminoglycosides were considered suboptimal as monotherapy in Gram-negative FN 
bacteremia ”…despite their in vitro activity and the minimal emergence of resistance 
strains (sic)” [Klastersky, 1993], even though aminoglycosides might reduce 
resistance to ȕ-lactams when used in combination [Gribble, et al., 1983] and augment 
bactericidal efficacy of synergistic ȕ-lactams [Klastersky, et al., 1982]. 
   The second EORTC trial [Zinner, et al., 1983] established that double ȕ-lactam 
therapy (carbencillin plus cefazolin) with aminoglycoside (amikacin) was not better 
than carbencillin plus amikacin alone. All the patients received the allocated antibiotic 
regimen “…for the first five days of therapy unless there was microbiologic 
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documentation of inadequate antibiotic therapy associated with poor clinical 
response.” The addition of new antibiotics classified the treatment response to trial 
antibiotics as a failure. “Improvement occurred in 35 (64 %) of 55 bacteremic patients 
treated with two antibiotics and 39 (65 %) of 60 treated with three antibiotics.” The 
abstract stated that “…the two antibiotic regimens were equal in efficacy and in 
nephrotoxicity.” The increased nephrotoxicity found with cephalothin in the first 
EORCT trial was not found with cefazolin in this trial, even though Luft [1982] 
grouped both these first-generation cephalosporins as agents with the potential to 
increase the nephrotoxicity when given in combination with an aminoglycoside.  
   Another conclusion from the second EORTC trial was that oral intestinal 
decontamination regimens resulted in fewer episodes of bacteremia, even though the 
study was not designed to test this effect [Zinner, et al., 1983]. Further, Klastersky, 
who participated in the writing committee, added a third conclusion in his 1993 
summary of these four EORTC trials “…that the early empirical use of granulocyte 
transfusions in combination with broad-spectrum antibiotics was not useful in the 
management of granulocytopenic cancer patients” [Klastersky, 1993; EORTC, 1983]. 
With “early”, Klastersky here meant prophylactic transfusions. Other studies had 
documented “beneficial” and even “lifesaving” effects of granulocyte transfusions 
from “related histocompatible donors” [EORTC, 1983] when given to patients with 
prolonged neutropenia and documented Gram-negative bacteremia. This did not 
appear in the original trial report; but the protocol paper explained that granulocyte 
transfusions were tested in a “poor prognosis” arm with available white blood cells for 
transfusion [EORTC, IATPG, 1977]. Prior to this trial, granulocyte transfusions had 
been considered effective in the management of pseudomonas septicemia [Frei, III, 
et al., 1965]. 
   The third EORTC trial [Klastersky, et al., 1986] compared three different broad-
spectrum ȕ-lactams, two penicillins (ticarcillin and azlocillin) and cefotaxime, all given 
with amikacin. All the patients were classified according to the results of their 
microbiological findings, and the focus was on patients with Gram-negative 
bacteremias.  In 83 episodes of Gram-negative bacteremias, the azlocillin-based 
regimen had the best result with a 66 % response rate, versus 37 to 42 % positive 
response rates with the two other regimens. All the Gram-negative bacilli were 
sensitive to amikacin. As expected from the first EORTC trial, patients with persistent, 
profound granulocytopenia had an even poorer response rate (37 %) than the 
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patients with rising granulocyte counts (73 %). “A logistic regression analysis 
indicated that the following factors also affected infection resolution: beta-lactam 
utilization in the regimen (azlocillin was better than ticarcillin or cefotaxime), 
resolution of profound granulocytopenia (< 100 cells per μl) during therapy, and 
susceptibility to the beta-lactam antibiotic” [Klastersky, et al., 1986]. The importance 
of the aminoglycoside was probably taken for granted. 
   The fourth EORTC trial [EORTC, 1987] introduced for the first time the question of 
whether a broad-spectrum ȕ-lactam would be efficient without the addition of an 
aminoglycoside. The assumption that an aminoglycoside was necessary for efficacy 
was so strong that even in this trial, amikacin was administered in all three arms 
starting the first day. However, a shorter course of amikacin was supposed to reduce 
the problem of nephrotoxicity. After three days, the amikacin was stopped in the arm 
consisting of ceftazidime plus the short course of amikacin. In the two other arms, 
amikacin was continued for nine days with either ceftazidime or azlocillin (the latter 
was the control arm based on the third EORTC trial). 
   After nine days, ceftazidime plus the long course (nine days) amikacin, 91 % of the 
patients had become afebrile which was the clinical definition of success. In the 
ceftazidime plus amikacin three days arm, and in the azlocillin plus amikacin nine 
days arm, the success rates were both 64 %. A Kaplan-Meyer plot registering the 
success of the patients for 14 days, showed that the proportion of success continued 
to drop after nine days. In the ceftazidime plus the long course amikacin arm the 
success rate ended at approximately 80 %. In the ceftazidime plus the short course 
arm the success rate ended at approximately 45 %, and in the azlocillin arm the 
success rate ended at approximately 20 % [Figure 1 in EORTC, 1987]. However, 
total deaths from the presenting infection was only 16 patients in total (< 2 %) of the 
872 evaluable patients, with no difference between the three arm of the trial, so most 
patients with failure must have responded to modifications of the initial antibiotic 
regimen.  
   Ceftazidime was a new anti-pseudomonal cephalosporin when this trial was 
conducted, and resistance to ceftazidime was unusual; as it often is when a new 
antibiotic is introduced. This trial also found that the median time to modification was 
more than six days in all the three regimens that were tested. Modification during the 
first three days was unusual and occurred in only 10 % of the patients in all the three 
arms.  
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Table 1 Summary of the four EORTC trials 
 
 
 
EORTC Year of Antibiotics Number with Number of Number of Number of 
trial  print tested improvement  Gram- Gram- deaths among
        positive negative evaluable 
        isolates isolates patients 
        in blood in blood   
              
1 1978 Carbencillin + gentamicin 110/156 (71 %)     41/453 (9 %) 
    vs Carbencillin + cephalothin 97/135 (72 %)     died from 
    vs Cephalothin + gentamicin 110/162 (68 %)     infection 
              
2 1983 Carbencillin + amikacin 158/224 (71 %)       
    vs Carbencillin + 142/195 (73 %)       
    amikacin + cefazolin         
              
3 1986 Azlocillin + amikacin 138/197 (70 %) 10/15 (67 %) 21/32 (66 %) 31 % total 
    vs Cefotaxime + amikacin 105/162 (65 %) 9/21 (43 %) 7/19 (37 %) 17 % single 
    vs Ticarcillin + amikacin 131/223 (59 %) 6/22 (32 %) 15/32 (47 %) Gram-negative
            bacteremia 
            4 % died from 
            superinfection 
            11 % died from
            
a non-
infectious 
            cause 
              
4 1987 Azlocillin +   19/37 (51 %) 16/40 (40 %) 13/298 (4 %) 
    9 days with amikacin         
    vs Ceftazidime +   8/23 (35 %) 20/42 (48 %) 13/266 (5 %) 
    3 days with amikacin         
    vs Ceftazidime +   14/30 (47 %) 38/47 (81 %) 8/308 (3 %) 
    9 days with amikacin         
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   In this fourth trial, there was a special focus on single-organism Gram-negative 
bacteremias. It occurred in 129 patients. The response rates in patients with single-
organism Gram-negative bacteremia were 81 % in the ceftazidime with the long 
course of amikacin, 48 % in the ceftazidime with the short course of amikacin, and  
40 % in the azlocillin plus nine days of amikacin arm [Table 3 in EORTC, 1987]. 
There may seem to be a contradiction between these results from patients with 
single-organism Gram-negative bacteremia and the results mentioned presented in 
page 13; however, the results in page 13 were based on treatment failure, previously 
defined as defervescence [Figure 1 in EORTC, 1987]. The difference was even more 
pronounced in patients with persistant < 0.1 x 109 granulocytes/L, with 50 % 
response rate in the ceftazidime with the long course of amikacin arm versus six 
percent response rate in the ceftazidime plus the short course of amikacin arm. The 
ten patients who developed a bacterial superinfection were mainly infected by Gram-
positive organisms. 
   As initial, empiric therapy aminoglycosides were potent drugs, even when given 
twice daily with probably frequent suboptimal peak concentrations. Compared to 
tobramycin and gentamicin the potency of amikacin is generally considered to be 
three times lower; suggesting that a daily dose of 15 mg/kg of amikacin should 
compare to 5 mg/kg of tobramycin or gentamicin [Gilbert and Leggett, 2008]. Dosing 
amikacin twice daily was standard therapy in all the three EORTC trials that used the 
aminoglycoside amikacin. The peak serum concentrations, based on amikacin given 
twice daily, would then probably not be high enough to prevent aminoglycoside 
adaptive resistance or resistant small-colony variants when amikacin had been used 
for nine days (see page 49) [Gilbert and Leggett, 2008]. This could be the reason for 
some of the late failures in the ceftazidime plus the long course of amikacin arm.  
   Based on these four trials Klastersky concluded in 1993 that ”the combination of an 
anti-pseudomonal ȕ-lactam with an aminoglycoside is recommended as the standard 
for empirical therapy in FN patients, especially in patients with severe and persistent 
granulocytopenia who have suspected or demonstrated Gram-negative bacillary 
bacteraemia. However, patients who are less neutropenic and/or less symptomatic 
may benefit from monotherapy.” [Klastersky, 1993]  
   In the publication “Why empirical therapy?” from 2009, Klastersky discussed why 
monotherapy with a broad-spectrum ȕ-lactam has later been proven as efficient as 
the combination of a ȕ-lactam with an aminoglycoside. He underlined that the 
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reasons for this were unclear, but pointed to several possible explanations. There 
might be “…improved intrinsic efficacies of antibiotics such as piperacillin-
tazobactam, ceftazidime, cefepime or the carbapenems…”. Further “…our practice in 
managing FN patients had changed so that prompt, earlier empirical therapy has 
become the norm.” Finally “More effective cytostatic chemotherapy leading to better 
remission of the underlying disease and perhaps the use of agents stimulating 
granulopoiesis may also have contributed.” He was still concerned about the 40 % 
case fatality rate in some groups of FN patients with Gram-negative bacteremia. 
Klastersky suggested that antimicrobial synergism may be important under these 
circumstances [Klastersky, 2009]. On one hand, these patients might have an 
invasive fungal infection. On the other hand, the possibility of a multiresistant 
superinfection might gradually become more and more important [Austin, et al., 1999; 
Goossens, et al., 2005; Haug, et al., 2011]. Another important reason why 
monotherapy with a broad-spectrum ȕ-lactam antibiotic might be as efficient as 
therapy with the combination of a ȕ-lactam with an aminoglycoside is that the impact 
of different kinds of extended spectrum ȕ-lactamases may not yet have been large 
enough to affect the microbiological epidemiology of FN [Bush and Jacoby, 2010]. In 
certain places in Asia the percentage of ESBL among the Gram-negatve bacilli is so 
high that it may be dangerous to treat FN with monotherapy broad-spectrum ȕ-
lactams [Peripi et al., 2012; Kumarasamy et al., 2010] . 
   These four EORTC trials all suffered from some weaknesses. At least the first and 
the second trials [Klastersky, et al., 1978; Zinner, et al., 1983], and maybe the third 
and the fourth [Klastersky, et al., 1986; EORTC, 1987] accepted patients to be 
randomized several times according to the trial protocols [Gaya, et al., 1975; Gaya, 
et al., 1977].  
   The episodes of FN were randomized, and the studies were described as “open-
labeled”. Blinding this kind of trial is possible, but it requires a huge amount of double 
book-keeping along with a logistically complicated organization conducting the trial.  
Only one RCT with double-blinding, comparing tobramycin once versus three times 
daily with a broad-spectrum ȕ-lactam antibiotic in FN children undergoing stem cell 
transplantation has been published [Sung, et al., 2003]. Sung and coworkers found 
less nephrotoxicity and more efficacy in the once daily arm. But Sung’s study was 
small, including only 60 episodes of FN, and it did not change the knowledge base on 
how to treat FN.   
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   Finally, the definition of the primary endpoint in the four EORTC trials was not 
optimal. An episode of FN may last for two to three weeks or more. Considering late 
modifications of the antibiotic regimens as failures, made it impossible to evaluate the 
initial effect of the antibiotic regimen. The situation in an oncological or hematological 
department is different. If the patient responds to the initial empiric antibiotic regimen 
and is clinically stable during the first three days of FN, then the initial antibiotic 
regimen should be considered successful [Feld, et al., 2003]. Later modification of 
the antibiotic regimen remains a secondary problem. New recommendations on how 
to conduct clinical trials in FN have adopted this way of evaluating responses [Feld, 
et al., 2003]. “Treatment failure should not be regarded as the primary outcome in 
open-label trials, as it reflects mainly treatment modifications” [Paul, et al., 2010]. 
   If the Norwegian regimen of penicillin G plus an aminoglycoside as the initial, 
empiric therapy in FN is successful during the first three days, the total consumption 
of broad-spectrum ȕ-lactams may be substantially reduced. This may be possible in 
many immunocompromised cancer patients, and in many patients with 
immunopathies, as well as in many patients who have had stem-cell or solid-organ 
transplantations. Initial, empiric therapy with penicillin G plus an aminoglycoside may 
have a substantial impact on the evolution, selection and spread of antibiotic 
resistance. 
 
2.2 The origin of The Tobramycin Trial 
 
   The Tobramycin Trial is the main result of this thesis. It was a Norwegian, 
multicenter RCT in hemodynamically stable FN patients. The study was researcher-
initiated and only sponsored by The Norwegian Radium Hospital.  
   At the turn of the century, most Norwegian institutions caring for FN cancer patients 
administered aminoglycosides three times daily, despite the fact that aminoglycoside 
given once daily had been introduced as standard practice in most other clinical 
situations (except primarily for bacterial endocarditis and pregnancy) [Cronberg, 
1993; Blaser, et al., 1994; Lund, et al., 1997; Berild, et al., 1999; Hansen, et al., 
2001]. The once daily dosing practice was based on the recent understanding of the 
aminoglycosides’ concentration-dependent bacterial killing [Craig, 1998]. The idea of 
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a toxic upper limit for aminoglycosides had been discarded about ten years earlier 
[Kumana and Yuen, 1994].  The Department of Hematology, Oslo University 
Hospital, had, however, already introduced gentamicin 7.5 mg/kg once daily with 
penicillin G in FN patients. Their experience was excellent [Lorentz Brinch, personal 
communication, 2000]. 
   An important question was if the aminoglycoside administered once daily had the 
same antibacterial efficacy as aminoglycosides given three times daily in FN patients. 
If the patient had a Gram-negative bacteremia, she would be without antibiotic 
coverage for more than 50 % of the time interval between two doses even when 
considering the post-antibiotic effect (PAE) of one to two hours. The PAE is longer 
the higher the serum concentration is, and shorter in patients with neutropenia. The 
PAE also depends on the bacterium, being longer for P. aeruginosa (1-3 hours), and 
not existing for Streptococcus pneumonia. A small inoculum, a high oxygen tension, 
and a high pH result in longer PAE. Imipenem, given with tobramycin or gentamicin, 
results in a longer PAE, while other ȕ-lactams do not affect the PAE of the 
aminoglycosides [Gilbert and Leggett, 2010]. 
   We wanted to examine if the difference between aminoglycosides given once or 
three times daily, with penicillin G, to cancer patients with FN had any clinical 
relevance. We chose to restrict the aminoglycoside to only one drug. One of the 
Norwegian experts in this field, Professor Johan Bruun, suggested that we used 
tobramycin, because, as he said: fewer clinical studies have been done with 
tobramycin than with gentamicin. Tobramycin was also the aminoglycoside most 
used at The Norwegian Radium Hospital where the trial was initiated. The trial was 
approved at the Institutional Review Board (IRB) at The Norwegian Radium Hospital 
as well as at The National Committee for Medical and Health Research Ethics (NEM) 
and at the other bodies that needed to approve the trial.   
 
2.3 Would inflammatory markers add to the clinical assessment? 
 
   The biology of immunosuppression caused by anti-cancer chemotherapy has been 
extensively studied [Engervall, et al., 1995; Buyukberber, et al., 2009]. The most 
important phenotypic manifestation of many anti-cancer chemotherapeutic regimens 
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is neutrophilic granulocytopenia, affecting one of the most important protective 
mechanisms of the innate immune response. These regimens also affect other parts 
of the immune response, both the non-specific and the acquired responses, causing 
a wide range of immunodeficiency syndromes with variable risks of opportunistic 
infections [Rauch, et al., 2012]. 
   Neutropenia is characterized by increased risk of early bacterial infections, 
secondary both to the neutropenia itself and also to the barrier breakdown of the skin 
from central venous catheters and mucositis-prone chemotherapeutic agents like 
methotrexate [Dahl, et al., 2009]. Long-lasting and deep neutropenia increases the 
risk for opportunistic infections. Herpes simplex reactivation is common, and 
prophylaxis with aciclovir is used. After three to five days of broad-spectrum antibiotic 
therapy in FN, systemic candidemia may occur even though the proven rate of 
invasive fungal infections in FN is < 5 % of all the positive blood cultures [Torfoss and 
Sandven, 2005]. Invasive mould infections may rarely occur, usually after more than 
twelve to fourteen days of neutropenia, especially if construction sites are present at 
or nearby the hospital with increased amounts of dust in the air [Ross, et al., 2011]. 
   The immunosuppressive condition caused by anti-cancer chemotherapy has led to 
research for inflammatory markers, primarily able to reflect and survey systemic 
bacterial infections. Developing tests that can rapidly detect induced inflammatory 
responses with high sensitivity and specificity that signal systemic bacterial infections 
and need of anti-bacterial therapy is a strong incentive for the pharmaceutical 
industry. From a more academic point of view, understanding the biology of 
neutropenia and inflammation is a driving force behind these developments. 
   So far, this research has not led to any laboratory test being more sensitive and 
specific than a detailed daily clinical examination of the FN patient. Some tests, 
however, have the potential to help in the diagnostic assessment, in particular 
procalcitonin (PCT) when used systematically and the results are immediately 
available to the clinician [Meisner, 2000; and Crist-Crain and Muller, 2005]. 
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2.4 Antimicrobial resistance when The Tobramycin Trial 
started 
 
   When The Tobramycin Trial was initiated the greater perspective was how we 
could contribute to an evolution where antibiotic agents remain effective and safe in a 
world with increasing antimicrobial resistance [Newton, 2005; Leibovici, et al., 2011]. 
This perspective is even more important today. In clinical situations where 
carbapenem- and multiresistant Gram-negative bacilli causes bacteremia and clinical 
sepsis [NORM/NORM VET, 2011], we have already returned to the early antibiotic 
era. Old, toxic antibiotics, like colistin, are being used more often, and some patients 
are again in need of granulocyte transfusions [Al-Tanbal, et al., 2010]. 
   The major strategies to prevent evolution and spread of antimicrobial resistance is 
using the antibiotic agents we have at hand in the most appropriate way, and to avoid 
unnecessary use of antibiotics [Jawetz, 1956; de Man, et al., 2000; Austin, et al., 
1999; Goossens, et al., 2005; Haug, et al., 2011; Gammelsrud, et al., unpublished]. 
Prevention of some infections by vaccination, and strict hospital and community 
hygiene practices, are the other main strategies. 
   Sepsis with bacteremia in FN will still continue to be a major risk factor affecting the 
optimal outcome in anti-cancer therapy. Documenting the efficacy and safety of the 
Norwegian antibiotic tradition with penicillin G plus an aminoglycoside as initial, 
empirical therapy in FN, is one important step in accord with these strategies. 
   Based on the fear of non-efficacy, the international medical community has been 
sceptic to a regimen based on the narrow-spectrum penicillin G in FN and other 
severe infections. We have, so far, not been able to give substantial theoretical proof 
or practical evidence for this efficacy. Thus, it has been even more important to 
present the Norwegian clinical experience, and the published evidence of the efficacy 
and safety of penicillin G plus an aminoglycoside, to the global medical community. 
   Only one clinical trial from The Netherlands has been published comparing 
penicillin G plus an aminoglycoside to broad-spectrum ȕ-lactam antibiotics, 
evaluating the effect on the colonizing microbial intestinal flora according to the 
antibiotic regimen used [de Man, et al., 2000]. Two neonatal intensive care units 
located on each side of a corridor were compared in a prospective cohort trial. The 
same number of patients was admitted to the two units (218 admissions to each unit). 
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There was always a shortage of unit beds and every new patient was admitted to the 
first unit that had a free bed. Unit A used intravenous amoxicillin plus cefotaxime and 
unit B used penicillin G plus tobramycin. Six months later, the units switched the 
antibiotic regimens (cross-over phase) to balance the effects of possible unit-related 
confounding variables.  
   Bacterial screening included cultures of respiratory aspirates and rectal swabs at 
admission and once a week thereafter. There were substantial differences between 
the two regimens with regard to the rate of colonization with Gram-negative bacilli. 
With the penicillin plus tobramycin regimen, E. coli predominated and made up 53 % 
of all the Gram-negative isolates. For the amoxicillin plus cefotaxime regimen, 77 % 
of all the Gram-negative isolates were Enterobacter species. The risk of colonization 
with resistant Gram-negative bacilli was expressed as colonizing events per 1000 
patient days. The most striking difference was found in the analyses of colonizing 
events with strains resistant to the agents of the empirical antibiotic regimen in use. 
Colonizing events with such strains occurred 18 times more frequently with the 
amoxicillin plus cefotaxime regimen. Enterobacter spp. bacteremia occurred only in 
the amoxicillin plus cefotaxime regimen. The total rate of bacteremias did not reach 
the 0.05 level of significance, but there was a trend towards fewer bacteremias in the 
penicillin plus tobramycin regimen (27 episodes versus 37 episodes, p = 0.22).  
   The flora of the body’s inner and outer surfaces forms a reservoir for opportunistic 
invasive infections. The 18-fold higher rate of colonization with resistant strains in the 
amoxicillin plus cefotaxime regimen probably put these children at a higher risk for 
nosocomial bacteremias with resistant bacteria. An antibiotic regimen in this 
population should not only treat the most common pathogens of neonatal septicemia, 
but it should also not contribute to selection of resistant nosocomial pathogens. With 
amoxicillin plus cefotaxime, they demonstrated a selective pressure toward ȕ-
lactamase producers that can degrade amoxicillin, for example Klebsiella spp. 
Further, Gram-negative bacilli such as Enterobacter spp. and Serratia spp. that can 
degrade cefotaxime and amoxicillin, might also have been selected [Filius, et al., 
2005]. The penicillin plus tobramycin regimen included a ȕ-lactam with minor effect 
toward Gram-negative bacilli. The use of an aminoglycoside was not associated with 
any significant emergence of resistance, since tobramycin only to a minor degree 
penetrated the mucosal surface of the gastrointestinal tract, and anaerobic conditions 
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counteracted the aminoglycoside that needed aerobic energy-production to be 
imported into the bacterial cells [Gilbert and Leggett, 2010]. 
   Except for the study of de Man and co-workers, all studies, to our knowledge, of 
penicillin G plus aminoglycoside have been conducted in Norway. The seven studies 
presented in Paper 1 consequently created the existing evidence for this antibiotic 
regimen. Three of the studies were published in Norwegian or presented at a local 
conference. The first study [Frøland, et al., 1989] was an important RCT, but 
unfortunately it was never published in a peer-reviewed journal. A Norwegian 
publication in preparation in 2012 [Gammelsrud, et al., unpublished] supports the 
findings of de Man and coworkers, as well as our conclusions in Paper 1 and 2.
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3. Materials and methods  
 
3.1 Material and methods of Paper 1 
 
The Norwegian experience with penicillin G plus an aminoglycoside as initial 
empiric therapy in febrile neutropenia; a review 
   “A [non-systematic] literature search in Medline and EMBASE was unable to 
identify other clinical studies of penicillin G and an aminoglycoside than the seven 
Norwegian studies presented here. Experts in the field are not aware of any other 
relevant studies” [Torfoss, et al., 2012]. When the studies were identified, the work 
that resulted in this paper mainly consisted in organizing and grouping the studies in 
a way that yielded meaningful results that could be compared to the international 
literature describing therapy based on broad-spectrum ȕ-lactam antibiotics [Paul, et
al., 2002; Freifeld, et al., 2011]. The seven studies were grouped and evaluated 
according to whether they studied the clinical response to FN therapy or 
microbiological sensitivities to penicillin G and to aminoglycosides. 
 
3.2 Material and methods of Paper 2 
 
Tobramycin once versus three times daily, given with penicillin G, to febrile 
neutropenic cancer patients in Norway: a prospective, randomized, multicentre 
trial  
   We decided to conduct a non-inferiority one-sided trial [Guyatt, et al., 2008] 
documenting that once daily dosing was at least as effective as three times daily 
dosings. The benefits of administering the aminoglycoside once daily were sufficient 
enough to change our practice if the result of the study would show that once daily 
dosing was not inferior to three times daily dosing. 
    We decided to follow the same formal procedures for material and methods that 
were used in the four major EORTC trials. Key points in these procedures included:  
1) Randomization of episodes of FN and not of patients; implying that patients could 
participate several times in the same trial [Gaya, et al., 1975; EORTC, et al., 1977]. 
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However, when analyzing and presenting the data, it was decided that each patient 
could be randomized only once (see pages 40-41). 
2) The primary endpoint was no modification of the initial antibiotic regimen during 
the full episode of FN, even if the modification occurred late in the treatment period 
[Gaya, et al., 1975]. 
3) Finally, randomization took place using numbered, sealed envelopes and not by 
computer or by calling a study center. Figure 1 (page 28) describes the distribution of 
episodes and the main explanations for episodes and patients that were not included 
[Gaya, et al., 1975; EORTC, et al., 1977]. 
   The Tobramycin Trial included patients with ”…cancer and febrile neutropenia. 
Neutropenia was defined as a neutrophil granulocyte count  0.5 x 109/L, and it had 
to be present twenty-four hours after randomization at the latest. Fever was defined 
as a temperature  38.0ƕ C. Age limits were sixteen to seventy years. A signed, 
informed consent was mandatory” [Torfoss, et al., 2007]. For practical reasons the 
temperature requirement was modified to one measurement  38.5ƕ C, or two 
measurements  38.0ƕ C over a time period of two hours. 
   “Exclusion criteria were: allergy to penicillins or to aminoglycosides, serum 
creatinine level >100 mol/L in women, or >120 mol/L in men, massive ascites, 
neurogenically decreased hearing or a vestibular dysfunction, treatment with 
nephrotoxic medications, such as cis-platinum, treatment with an aminoglycoside 
within the four weeks prior to randomization, parenteral antibacterial therapy within 
the last four days, pregnancy or nursing, or a hemodynamically unstable condition” 
[Torfoss, et al., 2007]. 
   Metronidazole therapy for anaerobic infections including Clostridium difficile toxin 
associated diarrhoea, trimethoprim-sulfamethoxazole (TS) given for Pneumocystis
jiroveci pneumonia prophylaxis, and antiviral- and antifungal therapy were allowed. 
For practical reasons, patients who did not tolerate  TS and who took dapsone 
instead, were equvally accepted for inclusion. 
   FN cancer patients constitute a heterogeneous group of patients [Klastersky, et al., 
2000]. Assuming that the outcome would vary among the participating cancer 
patients, we decided to randomize the FN episodes within each of three strata, 
defined as: 
1) Episodes with leukemia undergoing induction or consolidation chemotherapy. This 
is intensive chemotherapy with an expected long duration of neutropenia.  
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Figure 1 The randomization process of The Tobramycin 
Trial and the distribution of FN patients 
 
 
210 febrile episodes
Random allocation
Tobramycin x 1 Tobramycin x 3
Allocated:  104 episodes Allocated: 106 episodes
  Inclusion or exclusion criteria   Inclusion or exclusion criteria 
  violated prior to allocation: 9   violated prior to allocation:  11
Distribution of these 9 episodes Distribution of these 11 episodes
- no informed consent: 1 - no informed consent: 6
- older than 70 years :  2 - older than 70 years : 1
- randomization procedure
not followed : 2
-  randomization procedure
 not followed : 1
- patient not febrile : 1 - patient not febrile :  1
- elevated creatinine : 1 - elevated creatinine : 1
- tobramycin given within the 
last four weeks : 1
- allergy to penicillin : 1
- cis-platinum given 
recently :  1 
 Multiple randomizations :   9 Multiple randomizations :   6
Correct allocation:  89 patients* Correct allocation:  86 patients*
Received clearly lower doses of
tobramycin (< 5 mg/kg/day) : 2
Received other antibiotics than 
prescribed by the protocol :  1
Received clearly lower doses of
tobramycin (< 5 mg/kg/day) : 7
Received other antibiotics than 
prescribed by the protocol : 1
Other violations of the protocol: 10 Other violations of the protocol : 5 
Distribution of these 10 patients Distribution of these 5 patients
- no neutropenia at 24 hours :  7 - no neutropenia at 24 hours :  2 
- documented non-infectious cause
  for the fever: 3
- documented non-infectious cause
 for the fever : 2
- documented invasive Candida
 infection within four days and no
 bacterial infection :  1 
Lost to follow-up : 1* Lost to follow-up : 0
Per protocol participation in the
trial : 75 patients**
Per protocol participation in the
trial : 73 patients**
* The 174 evaluable patients are the patients with correct allocations (89 + 86 = 175) minus
the one patient lost to follow-up. ** Among the correctly allocated patients, several patients
had different kinds of protocol violations, leading to 148 (75 + 73) patients who remained
included according to all the protocol criteria.
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2) Episodes with lymphoma undergoing high dose chemotherapy with autologous 
stem cell support, for short called high dose chemotherapy (HDT). This is also a 
stratum of patients with an expected duration of neutropenia of more than a week. 
3) A stratum of other episodes with cancer, including leukemia and lymphoma 
episodes, receiving other anti-cancer regimens than the ones described above.  
   To avoid logistic problems in the randomization procedure, the different centers 
could chose to include episodes into only one or two of the stratification groups. No 
center randomized FN episodes into all three stratification groups.  
   Before starting the trial, our statistician estimated the needed sample size based on 
the following assumptions: 
- 15 % of the episodes were estimated to be non-evaluable. 
- The probability of a beneficial outcome, defined as ”No modification”, was estimated 
to be 30 to 50 %. The definition of the primary end point was ”No modification” of the 
initial, randomized antibiotic regimen during the episode of FN. Besides no 
modification of the antibiotic regimen, except for the above-mentioned exceptions, 
“No modification” included a sterile blood culture within 24 hours of the first positive 
blood culture, and survival until the patient had recovered from the FN episode. We 
followed the patients for until 30 days after randomization. This resulted in an 
estimated need for 210 randomized episodes. 
   For logistic reasons, not all the patients with a positive blood culture had the 
second blood culture drawn approximately 24 hours after the first blood culture. This 
was accepted, and only participants with a second blood culture were evaluated with 
regard to a possible positive second blood culture. 
   The trial started at The Norwegian Radium Hospital in the fall of 2001, and it was 
gradually expanded to include more centers in order to recruit the necessary 210 
estimated episodes of FN.  
   We used block-randomization to secure a balanced distribution of tobramycin once 
daily and three times daily in all the strata of FN episodes (diagnosis and planned 
therapy on the one side, and randomization center on the other side) participating in 
the trial [Guyatt, et al., 2008]. Numbered, computer-prepared, sealed envelopes in 
stacks of 24 were prepared at the study secretariat for each stratum at The 
Department of Clinical Research Support at The Oslo University Hospital; in 2001, 
Kontoret for Klinisk Forskning, at The Norwegian Radium Hospital.  
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3.3 Material and methods of Paper 3 
The mild inflammatory response in febrile neutropenic lymphoma patients with 
low risk of complications is more pronounced in patients receiving tobramycin
once daily compared with three times daily 
   Patients in The Tobramycin Trial [Torfoss, et al., 2007] at The Norwegian Radium 
Hospital gave their informed consent to collect extra blood samples in order to study 
inflammatory markers when the clinical trial was completed. Serum and EDTA-
plasma samples from 61 patients in the HDT arm were collected and frozen at - 70ƕC. 
   Sample one was collected when the FN episode started, but before the first dose 
of antibiotics was given (serum and, or EDTA-plasma were collected in 53 to 56 
patients; depending on the laboratory test performed, Table 2, Paper 3).    
   Sample two was collected one to two days later (median 24 hours; range 16 to 56 
hours later), when the first tobramycin serum concentration sample was collected 
(serum and, or EDTA-plasma were collected in 60 to 61 patients; depending on the 
laboratory test) according to the protocol. 
   We examined the following markers: 
C-reactive protein (CRP) was examined in EDTA-plasma and determined by a high-
sensitive particle-enhanced immunoturbidometric assay (Roche Diagnostica, 
Mannheim, Germany) by technical biochemistry personnel at the Department of 
Medical Biochemistry at The National Hospital, Oslo University Hospital. 
PCT was determined in EDTA-plasma by the BRAHMS PCT-sensitive KRYPTOR 
Model F Mono Cavro (Brahms Diagnostica, Hennigsdorf, Germany) at The 
Norwegian Radium Hospital, Oslo University Hospital, in cooperation with technical 
biochemistry personnel. 
The C3 complement activation product C3bc and the terminal, soluble C5b-9 
complex (TCC) were quantified in EDTA-plasma using enzyme-linked 
immunosorbent assay (ELISA) at The National Hospital, Oslo University Hospital. 
Mannose-binding lectin (MBL) was quantified in EDTA-plasma by a double 
antibody ELISA at The National Hospital, Oslo University Hospital.   
A 17-kit cytokine assay was examined in serum with Bioplex cytokine assays (Bio-
Rad Laboratories, Hercules, CA, USA) at The Norwegian Radium Hospital.  
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Table 2  Normal values* and cytokine values (according to 
Biorad, CA, USA). Modified from Table 2, Paper 3 
 
 
Analyses Normal values Samples          Sample 1 
  and   Median Range 
  Cytokine values      
  from Biorad       
CRP < 10 55 16 1 - 197 
PCT < 0.5  55 0,13 0,05 - 0,89
          
C3bc < 20 53 49 14 - 163 
TCC < 1.0 53 0,7 0 - 8,2 
MBL < 100 = deficient 53 2603 0 - 7772 
  < 400 = decreased       
IL-1ȕ undetectable -15 56 0,7 0 - 341 
IL-2 < 7 56 0 0 - 10 
IL-4 undetectable - 13.1 56 0 0 - 1,6 
IL-5 < 5 56 309 2 - 4057 
IL-6 undetectable - 8.5 56 61 6 - 513 
IL-7 0.27 - 8.7 56 3,0 0 - 14,0 
IL-8 undetectable - 47 56 31 7 - 305 
IL-10 < 1 56 0,1 0 - 22 
IL-12 40.4 - 150 56 0,3 0 - 16 
IL-13 undetectable - 79 56 0 0 - 6,6 
IL-17 < 31 56 0 0 - 0,74 
G-CSF   56 135 0 - 1845 
GM-CSF < 3.9 56 0 0 - 40 
INF-Ȗ undetectable - 5.6 56 9 0 - 119 
MPC-1 26.9 - 375.5 56 316 83 - 2797 
MIP-1ȕ 24 - 211 56 142 58 - 425 
TNF-Į undetectable - 20 56 8 0 - 86 
 
* Units are for CRP: mg/L, for PCT: μg/L, for C3bc and TCC, AU/mL, for MBL: μg/L, and for 
the different cytokines: ng/L. For other comments, see Table 2, Paper 3. 
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The 17 cytokine kit contained interleukin (IL) IL-1ȕ, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,  
IL-10, IL-12, IL-13, IL-17, granulocyte colony-stimulating factor G-CSF), granulocyte 
macrophage-CSF (GM-CSF), interferon Ȗ (INF Ȗ), monocyte chemoattractant protein  
1 (MCP-1), macrophage inflammatory protein 1ȕ (MIP-1ȕ), and  
tumor necrosis factor Į (TNFĮ). 
   No conventional normal values have been established for the 17 cytokines. Another 
Norwegian research team surprisingly found serum concentrations below the 
detection level in several of the cytokines they examined. They then asked the 
manufacturer if normal values existed. The research department at Biorad had, in 
fact, suggested a set of normal values, but these values had not been formally 
validated [personal communication, Tor Erling Lea, Norwegian University of Life 
Sciences, Department of Chemistry, Ås, Norway; 2011]. These manufacturer-based 
normal values are presented in the Table 2 page 31 above. 
   The set of inflammatory markers was analyzed for the whole series of FN patients, 
(Table 2, Paper 3), and then the results were compared between the two trial arms 
(Table 3, Paper 3). 
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4. Brief summary of the results 
 
4.1 Paper 1 
 
The Norwegian experience with penicillin G plus an aminoglycoside as initial 
empiric therapy in febrile neutropenia; a review 
   The occurrence of antibiotic resistance and the use of broad-spectrum antibiotics 
are relatively low in Norway [NORM/NORM VET, 2011; Goossens, et al., 2005].  
The national and local recommendations for antibiotic therapy in FN and in sepsis of 
unknown origin are to start with penicillin G plus an aminoglycoside [von der Lippe, 
2001; NORM, 2011; Torfoss and Høiby, 2010]. There are reasons to assume that this 
regimen contributes to the prevention of antibacterial resistance [de Man, et al., 2000; 
Gammelsrud, et al., 2011]. 
   In a situation with increasing world wide antimicrobial resistance and few new 
antibacterial drugs being developed [Newton, 2005], the initial choice of penicillin G 
plus an aminoglycoside may be one of the strategies to keep antibacterial drugs 
effective for future patients [Leibovici, et al., 2011]. 
   Seven studies were reviewed of which, unfortunately, only four have been 
published in international peer-reviewed journals. Clinical outcomes and, or the 
sensitivities of the blood culture isolates for penicillin G and for the actual 
aminoglycosides, were the results reported in the studies. A summary of the five 
studies that reported the clinical outcome (781 episodes) in episodes treated with 
penicillin G plus an aminoglycoside, demonstrated that 53 % of the episodes had 
antibiotic modifications during the episodes of infection. The overall success rates 
(survival) were 90 - 100 % when episodes where the antibiotic regimen had been 
modified were included. The total case fatality rates after the onset of infection were  
5 - 10 %, and the case fatality rates related to the initial therapy with penicillin G plus 
an aminoglycoside were 0 - 1 %. The number of days before the antibiotic 
modifications took place was only reported in one trial [Torfoss, et al., 2007]. In this 
trial, the mean time interval to modification was five days. In comparison, the fourth 
EORTC trial found a median time to modification of more than six days. 
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   Four studies reported the microbiological sensitivities of Gram-positive bacteria  
(314 isolates) toward penicillin G. It was 49 %. Sensitivity toward aminoglycosides 
was 57 %. Unfortunately, no information on the combined sensitivities was reported. 
For the Gram-negative bacteria (308 isolates), sensitivity toward the relevant 
aminoglycoside (netilmicin, gentamicin or tobramycin) was 99 %. 
   These two qualitatively different outcomes could not be unified into one parameter, 
even though there might be an association between the two. Still, together they give 
a reasonable picture of the microbiological epidemiology, and of the clinical 
outcomes, when choosing penicillin G plus an aminoglycoside in patients with 
malignant disease and fever. The majority of the cases suffered a hematological 
malignancy. The number of patients who were in septic shock was only reported in 
one trial [Torfoss, et al., 2007], which specified that hemodynamically unstable 
patients were excluded from participation in the trial. Medical tradition in Norway has 
been to provide patients in septic shock with double Gram-negative antibiotic 
coverage [Torfoss and Høiby, 2010]. Septic shock is relatively unusual in FN 
[Klastersky, et al., 2000], therefore hemodynamically unstable patients were probably 
relatively unusual among the patients included in the seven studies in this report. 
   An additional comment to these results is the similar conclusions of all the seven 
studies: initial therapy with penicillin G plus an aminoglycoside was efficacious and 
safe, provided the regimen was modified when the clinical development was not 
satisfactory. 
 
4.2 Paper 2 
 
Tobramycin once versus three times daily, given with penicillin G, to febrile 
neutropenic cancer patients in Norway: a prospective, randomized, multicentre 
trial  
   Two hundred and ten episodes were included and randomized into one of the two 
main study arms between 2001 and 2005. During the study, our statistician and 
others forwarded strong arguments that patients should only be included once; as 
was also later recommended by Guyatt and coworkers [2008]. Accordingly, we 
decided to only present the results of the first randomizations. A total of 174 patients 
were considered evaluable. 
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   The overall result was that 40 % of the evaluable patients in both study arms had 
”No modification” of the antibiotic regimen. Furthermore, the two arms did not differ 
with regard to toxicity. 
   The mean time until treatment modification was five days; with no difference 
between the two arms. Modifications during the first three days occurred in 18 
patients (10 %); the same as in the fourth EORTC trial [EORTC, 1987]. 
   Thirty-one (18 %) of the 174 evaluable patients had a positive blood culture. This 
was slightly lower than the combined results from the four EORTC trials. This may be 
due to the fact that patients in suspected septic shock (hemodynamically unstable 
patients) were excluded from our trial. Patients in septic shock were routinely treated 
with a broad-spectrum ȕ-lactam antibiotic plus an aminoglycoside (double Gram-
negative coverage). Otherwise, our distribution of the classification of the febrile 
episodes was similar to most other similar clinical antibiotic trials in FN. 
   With regard to nephrotoxicity, the mean increase in serum creatinine was only 
seven μmol/L (95 % CI: 6 – 9 μmol/L) with no difference between the two arms.  
Ten patients, five in each arm, had an increase of more than 50 % from their baseline 
creatinine serum concentration [Mavros, et al., 2011]. The highest absolute elevation 
in serum creatinine in any one patient was 47 μmol/L. No other serious adverse 
events were reported.  
   All our FN patients survived 30 days after the randomization; except for one patient 
who expired 29 days after randomization, several weeks after the HDT discharge. 
She died from a suspected respiratory infection (further described in the Discussion, 
page 47). 
  
4.3 Paper 3 
 
The mild inflammatory response in febrile neutropenic lymphoma patients with 
low risk of complications is more pronounced in patients receiving tobramycin
once daily compared with three times daily 
   The third of our aims was to characterize the inflammatory response in FN patients 
and evaluate if any of the inflammatory markers examined could be sensitive and 
specific enough to influence the therapeutic decisions in initial FN. However, as all 
the participants turned out to be patients with low risk of complications, we were 
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unable to make any conclusions as to our hypothesis. “The results reflect only the 
situation in patients with a benign course of FN, and they say nothing about the 
inflammatory response in patients with Gram-negative sepsis or a more severe 
course of FN” [Torfoss, et al., 2011]. 
   Sixty-one of the HDT patients from The Norwegian Radium Hospital participating in 
The Tobramycin Trial had given blood samples that were analyzed. The patients 
constituted a clinical homogeneous group with a benign initial course. These 61 
patients remained neutropenic for a median time of 10 days (range 5 - 16 days). 
Thirty-two patients received tobramycin once daily and 29 patients three times daily. 
Four patients had a positive blood culture; three grew Gram-positive viridans 
streptococci and one a coagulase-negative staphylococcus.  
   The analyses revealed a mild increase in the proinflammatory cytokines in both 
samples, as well as from the first to the second sample.    
   CRP was a non-specific parameter in the assessment of the severity of the clinical 
condition.  
   PCT results were in accord with previous research that has shown a value  
< 0.5 μg/L to be a strong, negative predictor for bacteremia [Christ-Crain and Muller, 
2005].  
   The complement activation factors showed a mild increase; this supported the 
notion of a mild sterile inflammation.  
   MBL values were deficient in five patients, and decreased in five other patients. All 
of these patients had a clinical course similar to the other patients. However, one of 
the patients with a decreased MBL level was the one who died 29 days after 
randomization (see page 47).  
   The 17 cytokines showed a mild increase in the proinflammatory cytokines from the 
first to the second sample (primarily IL-6, IL-8, INF-Ȗ, and TNF-Į); supporting the 
notion of a mild sterile inflammatory response. The only cytokine with a significantly 
reduced concentration in the second sample compared to the first sample was IL-5. 
This cytokine is associated with eosinophil activation [Sanderson, 1992], allergies 
and a TH 2 cytokine pattern [Upadhyaya, et al., 2011]. 
   When comparing the results of the two tobramycin arms, most of these results did 
not differ significantly. However, there may have been a trend that the patients who 
had received tobramycin once daily had higher proinflammatory cytokine values 
compared to those who had received tobramycin three times daily. This trend may be 
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difficult to evaluate since the interindividual differences may be substantial [Wong,  
et al., 2008]. 
   We concluded that none of the inflammatory markers in this series of FN patients 
correlated better with the clinical outcome of the FN episode than daily and thorough 
clinical examinations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38
5. Discussion 
 
5.1 Evaluation of the three papers 
 
   The main strength of this thesis is the fact that we conducted a clinical RCT and 
found and documented that penicillin G plus tobramycin was effective and safe as 
initial, empiric therapy in hemodynamically stable FN patients (Paper 2) [Torfoss,  
et al., 2007].   
   The focus of the trial was tobramycin once versus three times daily. As most similar 
trials, including the four EORTC trials, this was an open-label trial. Once the 
randomization envelope was opened, the treatment regimen was known to the 
physicians taking care of the patient, including the physician who made the decision 
of antibiotic modification, the critical event that could alter the outcome of the trial for 
that patient. 
   The results of the study were similar in the two randomized treatment regimens in 
all the different arms and subgroups of patients who took part in the trial, as 
documented in Tables 3 and 4, Paper 2. This supported the assumption that there 
was no major bias to modify the antibiotic regimen depending on the randomization 
arm of the patient. The conduction of the trial at The Norwegian Radium Hospital 
gave the principal investigator, who was also the local investigator, the impression 
that the decisions to modify the antibiotic regimen depended on the clinical conditions 
of the patients, based on the clinical traditions at the institution; and not on the fact 
that the patient took part in a clinical trial evaluating the initial antibiotic regimen 
administered to the patient. It is reasonable to assume that the situation have been 
similar at the other participating institutions.  
   At the closure of the trial, 100 of the 210 included episodes were randomized at 
The Norwegian Radium Hospital. The rest of the episodes were randomized in 
various numbers (range 1 – 39) at the other participating institutions. 
   Our experience from The Norwegian Radium Hospital was that the stack of 
envelopes and the equipment necessary for inclusions and randomizations (informed 
consent-forms, new empty CRF-forms etc.) needed to be checked almost every day. 
A method that worked well consisted of giving the necessary information about the 
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study to the doctors coming on call at the daily afternoon report meeting. However, 
this was labor-intensive and required a persistent dedication from the local 
investigator. 
   In the end, we were able to complete the trial as planned. The measures of 
gradually recruiting new centers into the trial and the monthly bulletin sent to all the 
local coordinators made it possible to keep a quite constant randomization rate; as is 
shown in Figure 2 below. 
  
Figure 2 Accumulated number of randomizations  
per month in The Tobramycin Trial 
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   The four EORTC trials focused on the antibiotic response in patients with Gram-
negative bacteremia. In our study, 31 patients (18 %) had bacteremias. In the once 
daily arm there were 13 bacteremias, and in the three times daily arm, there were  
18 bacteremias. Four Gram-negative bacteremias occurred in the once daily arm, 
and two of those (50 %) had a successful “No modification” outcome. Seven Gram-
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negative bacteremias occurred in the three times daily arm, and none of them had a 
“No modification” outcome. These numbers are small, but they may at least support 
the hypothesis of the trial. Tobramycin once daily is at least as efficient as tobramycin 
three times daily. 
   Eight of the eleven participating centers randomized  12 episodes of FN each. We 
therefore decided not to present results for the individual centers. The difference in 
successful ”No modification” between the intensive leukemia stratum (in total 40 %) 
that was randomized at several different centers, and the HDT lymphoma stratum (in 
total 16 % “No modification”) that was only randomized at The Norwegian Radium 
Hospital, can only be explained by different clinical traditions. More than 20 
oncologists participated in the on-call pool at this institution; most of them worked 
with solid tumor patients who did not have neutropenia of long duration. Therefore, 
since HDT was initiated at this institution 20 years ago, there has been a consistent 
practice to inform the on-call team with detailed suggestions on how to handle HDT 
patients with probable deteriorating clinical situations. This information has been 
given both orally, in a clinical discussion at the afternoon report meeting, and as a 
written report in the patients’ charts. Still, when an HDT patient had persistent fever 
during a night- or weekend shift of an oncologist who did not work daily with 
lymphoma patients, the oncologist might have had a tendency to modify the antibiotic 
regimen sooner than our more experienced lymphoma-oncologists. This happened in 
spite of repeated suggestions of starting the diagnostic work-up of fever during the 
on-call period, and to await antimicrobial modification until the patient’s regular doctor 
would take care of the patient the next day. 
   The study of Tangen [Tangen, et al., 1999] observed the same phenomenon. 
Similar patients with leukemia and FN receiving penicillin G plus an aminoglycoside 
had a ”No modification” rate of 48 and 50 % at two of the three participating centers 
whereas the ”No modification” rate was only 8 % at the third center. The reason for 
these differences must be other than purely medically based. 
   In our RCT,  “The patients were stratified by study center and by three combined 
diagnosis and treatment groups: (i) acute-leukaemia-receiving-intensive-
chemotherapy; (ii) malignant- lymphoma-undergoing-intensive-chemotherapy-with-
autologous-stem-cell-support; (iii) other-cancer-patients, including leukaemia and 
lymphoma patients not receiving the above mentioned therapies. Block 
randomization was done by the computer using random block sizes of four and six 
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episodes and presented at the participating centres in sealed, consecutive, pre-
numbered envelopes. The envelope with the lowest number was drawn when an 
eligible patient developed febrile neutropenia” [Torfoss, et al., 2007].  
   The plan behind this stratification strategy was to study patients with different 
expected risks of complications, mainly based on different expected durations of 
neutropenia [Guyatt, et al., 2008]. The stratum of  ”other” patients was planned to 
consist of patients with solid tumors and short periods of FN. However, most of the 
“other” patients (47 of 66) turned out to be leukemia and lymphoma patients who had 
received other anti-cancer chemotherapy regimens than the ones specified as 
initiation and consolidation chemotherapy in leukemia patients and HDT in lymphoma 
patients. Some of these anti-cancer chemotherapy regimens were followed by long 
periods of neutropenia. 
   Even though the total results would not have been affected by a different 
stratification strategy, we might have found a somewhat different distribution of the 
results if we had used two stratification groups, one with an expected long period of 
neutropenia and one with an expected short period. The low rate of “No modification” 
at The Norwegian Radium Hospital would have been discovered by combining the 
results from each participating institution and the reported diagnostic code. 
   We recorded time to defervescence in episodes with a successful “No modification” 
outcome. There was no difference between the two arms. A preliminary Kaplan-
Meyer plot of time to defervescence in patients with a “No modification” outcome, 
showed two almost identical curves (results not shown). “The highest mean serum 
creatinine after therapy with tobramycin (n = 172) was 69 mol/L (95% CI: 66 - 71 
mol/L) and the mean increase in serum creatinine (n = 169) was seven mol/L  
(95% CI: 6 - 9 mol/L), with no difference between the two arms. The highest 
absolute elevation in serum creatinine was 47 mol/L. No ototoxicity or other side 
effects were reported” [Torfoss, et al., 2007]. However, no audiometry analyses were 
performed. We tried to do audiometry at The Norwegian Radium Hospital when we 
started the study, but after a short time we realized that the logistics did not work in 
the busy pre-HDT period of these patients, so the protocol was amended and the 
requirement for audiometry was suspended. 
   A metaanalysis on nephrotoxicity in FN patients who received aminoglycoside once 
or multiple times daily was published in 2011. At the request of the researchers of 
this metaanalysis, we calculated the number of patients who had an increase in 
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baseline serum creatinine of more than 50 %; and we found this to be ten patients 
[Mavros, et al., 2011]. Our contribution was acknowledged at the end of their 
publication. 
    As a conclusion to the question of how to monitor aminoglycoside serum 
concentrations, when aminoglycosides are administered once daily, in a dose of at 
least 6 mg/kg, the peak serum concentration will almost always be > 12 mg/L. For all 
practical purposes this is > 10-12 times the MIC of most the common bacterial 
isolates found in bacteremias of FN patients in Norway [Craig, 1998]. The 2011 
survey of serum aminoglycoside concentrations at The Norwegian Radium Hospital 
found a median peak concentration of 16.0 mg/L (range: 8.1 to 32.4 mg/L). 
Unfortunately, lower doses than six mg/kg are still occasionally administered, 
probably explaining the lower end of this range interval. A similar survey at The 
Norwegian Radium Hospital from before The Tobramycin Trial (in 2001), when 
aminoglycosides were administered three times daily, showed that 25 % of the peak 
concentrations were < 8 mg/L. When dosing the aminoglycoside once daily, the only 
monitoring that usually remains important is the trough serum concentration to avoid 
accumulation of aminoglycosides with risk of nephrotoxicity and ototoxicity. 
   Other outcomes of The Tobramycin Trial were less labor-intensive treatment, 
administering aminoglycosides once daily compared to three times daily. During the 
trial a couple of experienced nurses were observed, and the time they used to 
prepare and administer a dose of tobramycin was found to be approximately 15 
minutes. Collecting samples for trough and peak serum concentrations in addition to 
the administration of the aminoglycoside dose, in general required one hour. 
   In The Tobramycin Trial, we changed the decision of the evaluability of the patients, 
specifically to include only the first episode of FN in the patients who were 
randomized several times. This was done before the results were analyzed. 
Originally, patients could participate in the study several times, as had been the 
practice in the EORTC trials [Gaya, et al., 1975; and EORTC, 1977]. Before 
analyzing the results we decided that only values from the first episode of FN should 
be included in the analyses. The reason for this is that it is known that patients who 
have had one episode of FN have a higher risk of FN after the next anti-cancer 
chemotherapy regimen [Aapro, et al., 2011]. This caused 15 episodes in 11 patients 
to be withdrawn as non-evaluable. Altogether 17 % (36 FN episodes) ended up being 
non-evaluable (see Figure 1, page 28). 
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   A total of 210 episodes of FN in 199 patients were randomized. More than one 
randomization occurred 15 times. The 15 “double or triple” randomizations is thus 
explained by seven patients randomized two times and four patients randomized 
three times. This comes down to seven episodes in the seven patients randomized 
twice and eight episodes in the four patients randomized three times. Seven plus 
eight makes the 15 episodes that were randomized more than once.  
   As Figure 1 explains, a total of 174 patients were considered evaluable. The results 
for these 174 patients were erroneously presented as an intention-to-treat (ITT) 
analysis [Torfoss, et al., 2007]. The need to correct the use of the word “ITT” was first 
discovered when this thesis was written. We here present an analysis based on a 
review of the available study material. Unfortunately, some of the local investigators 
did not fill in the case report forms (CRF) when they realized that the patient would 
not be evaluable. Because of this, we are only able to present results for 196 of the 
199 patients. In total, 83 of 196 patients (42 %) had a recorded “No modification” 
outcome. In the tobramycin once daily arm 44 of 101 patients (44 %), and in the 
tobramycin three times daily arm 39 of 95 patients (41%) had a successful “No 
modification” outcome. We conclude that this analysis shows results similar to the 
analysis of the 174 published “evaluable” patients (Paper 2). Tobramycin once daily 
is as effective and safe as tobramycin three times daily, given with penicillin G, as 
initial, empiric therapy in FN cancer patients. 
 
   Paper 1. The seven Norwegian studies consisted of two RCTs and five 
observational studies. The first RCT [Frøland, et al., 1989] was conducted in the 
1980s in a single institution. They compared episodes of FN treated with penicillin G 
plus netilmicin versus ceftazidime monotherapy. Their hypothesis was that 
ceftazidime monotherapy was as effective as penicillin G and netilmicin. They found 
that there was no statistical difference neither between the patients nor between the 
two antibiotic regimens.  
   In the 1980s, the question of whether broad-spectrum ȕ-lactam monotherapy was 
as effective as a combination of a broad-spectrum ȕ-lactam plus aminoglycoside was 
raised. This question was also the focus of the forth EORTC trial, where ceftazidime 
given with a long (nine days) course of amikacin had a significantly higher success 
rate than ceftazidime given with a short (three days) course of amikacin [EORTC, 
1987]. However, the belief in the fourth EORTC trial seemed to be strong that 
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treatment with an aminoglycoside for at least some days was necessary. And, as we 
have seen, the addition of an aminoglycoside has benefits [Klastersky, 1990], and not 
only negative side effects.  
   The initiative by Frøland and coworkers to compare the Norwegian regimen with 
the narrow-spectrum ȕ-lactam, penicillin G plus netilmicin was both innovative and 
important at the time, both with regard to the Norwegian antibiotic tradition, and as an 
argument for penicillin G plus an aminoglycoside in the international discussion, even 
though the hypothesis of their trial was to examine if ceftazidime monotherapy was a 
desirable antibiotic regimen in Norway. Unfortunately, since the study of Frøland and 
co-workers was never published in a peer-reviewed journal, it did not get international 
scientific attention. Today, unfortunately, it is difficult to find the document from the 
symposium. The complete manuscript was written in Norwegian in the Glaxo-
sponsored Norwegian Ceftazidime-Symposium publication (Norsk Ceftazidim-
symposium) held in 1989 [Frøland, et al., 1989]. 
   Many international studies with a broad-spectrum ȕ-lactam with and without 
aminoglycosides were undertaken at about the same time. This resulted in broad-
spectrum ȕ-lactam monotherapy becoming accepted as the international standard of 
care. Especially monotherapy with ceftazidime became the drug of choice at many 
institutions, based on a long list of RCTs where ceftazidime was compared to 
different other broad-spectrum regimens. A Pub-Med search based on the key words 
“febrile neutropenia” and “randomized clinical comparison with ceftazidime” gave 18 
hits. Five studies in which ceftazidime monotherapy was compared with other 
different antibiotic regimens, conducted before the year 2000, concluded that 
ceftazidime was as effective as the other regimens consisting of one of the following 
antibiotics: ciprofloxacin, cefepime, imipenem, or piperacillin [Bayston, et al., 1989; 
Perkkiø, et al., 1990; Dranitsaris, et al., 1995; Freifeld, et al., 1995; and Aparicio, et
al., 1996]. One trial published after the year 2000 found cefepime equivalent to 
ceftazidime monotherapy [Kebudi, et al., 2001]. The other publications were a review 
[Paul, et al., 2010] and trials where ceftazidime was given with an aminoglycoside. In 
one study, ceftazidime was compared with trimetoprim-sulfamethoxazole plus 
amikacin. In only one trial ceftazidime monotherapy came out slightly inferior  
(38 % success) to imipenem (50 % success) [Rolston, et al., 1992]. 
   In conclusion, ceftazidime was considered as effective as any other broad-
spectrum ȕ-lactam. This gave an unfortunate credit to ceftazidime as the drug of 
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choice for empirical therapy in FN. The problem was that ceftazidime was one of the 
few antibiotics available as treatment for pseudomonas infections. Ceftazidime 
should therefore be reserved for treatments of proven or suspected pseudomonas 
infections. When ceftazidime is regularly used in FN as the drug of empirical choice 
we risk loosing ceftazidime as a tool for dealing with often difficult to treat 
pseudomonas infections because of increasing resistance,  
   A Danish study [Hansen, et al., 1988] that evaluated aminoglycoside dosing once 
or three times daily, added to our evidence base before we started The Tobramycin 
Trial. This RCT used a today relatively narrow-spectrum ȕ-lactam, the second 
generation cephalosporin, cefuroxime, along with netilmicin. Sixty-four episodes of 
suspected septicemia in 56 immunocompromized patients (mainly hematological 
cancer patients), were analyzed. They found that patients given netilmicin once daily 
defervesced sooner than those given netilmicin three times daily. Otherwise the 
outcomes were similar. Cefuroxime is no longer a very effective Gram-negative 
antibiotic agent. In general, its MIC values for the common Gram-negative bacilli are 
ten to 30 times higher than the MICs of cefotaxime [Andes and Craig, 2010].    
   Results from another Danish study [Freundlich, et al., 2007] have supported the 
findings of the seven Norwegian studies. It was a retrospective analysis based on 
patients who had received appropriate antibiotic therapy for registered bacteremias. It 
found that the cumulative 30 day case fatality rate was 17 % in an aminoglycoside 
plus a ȕ-lactam cohort (the ȕ-lactams most used were penicillin G, ampicillin and 
cefuroxime) and 18 % in a non-aminoglycoside cohort (in most episodes an 
aminopenicillin or cefuroxime were given as monotherapy). The editorial commentary 
to this study [Leibovici and Paul, 2007] concluded, ”In countries where the resistance 
is low enough to use ”old” ȕ-lactams, and there is an unwillingness to use broad-
spectrum ȕ-lactams, evidence for the efficacy of combination treatment and for its 
role in keeping the resistance at a low level is wanting.” Northern Europe, including 
Scandinavia, belongs to those countries. However, on the background of changing 
epidemiology, such evidence is only valid for the time the study took place, unless 
close surveillance of clinical results and antibiotic resistance is carried out 
continuously. However, it was important that a famous international peer-reviewed 
journal like The Journal of Antimicrobial Chemotherapy for the first time in history 
became the international “spokesperson” for a policy that was sympathetic toward the 
restrictive Scandinavian antibiotic traditions. 
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   Paper 3. The study of inflammatory markers. FN is a heterogeneous condition; 
but most of the patients with FN belong to the group of patients with little risk of 
complications [Klastersky, et al., 2000]. Thus, even though the patients in the Paper 3 
study are not representative for all patients with FN, they still belong to the large 
group of low risk lymphoma HDT patients who can be identified by a MASCC-score  
 21.The results from this study of low risk patients may serve as a useful comparator 
for similar studies in the future. 
   Our conclusion and suggestion in the headline of the paper, that this mild 
inflammatory response is more pronounced in patients receiving tobramycin once 
daily compared to three times daily, cannot be more than a suggestion of a possible 
trend.  
   We measured inflammatory markers, cytokines and MBL in blood samples from our 
patients. It is worth remembering that other possibilities of bias also may be 
important. The values we found in the blood samples were not necessarily the same 
values that might have been found at the local infection sites of infection. Still, in FN 
with bacterial infections, the site of infection may primarily be systemic, even though 
the origin of the infection will always be local. In FN, oral mucositis, local central 
venous catheter infections, and infections originating in the colonic part of the 
gastrointestinal tract are the most common local sites for the origin of systemic 
bacterial infections. However, it may be almost impossible to measure inflammatory 
markers at these sites. Blood cultures will almost always be the surrogate sample for 
the early site of infection, and the samples available for early, rapid analysis. 
   Another consideration of possible bias may be the handling of the samples before 
the analyses. Our experience at The Department of Medical Biochemistry at The 
Norwegian Radium Hospital is that this variation may be more important than 
previously estimated [personal communication, Trine Bjøro and Nils Bolstad, June 
2012]. Different handling of the samples may affect the results of the individual 
samples. In our study, however, all the samples were handled simultaneously and in 
the same way, and all the serum and plasma samples were frozen within two hours 
after collection. This should suggest a reasonably similar treatment of the samples. 
But, in order to be able to prepare and conduct analyses in several different 
laboratories, the samples had to be thawed and refrozen more than once.  
   Finally, it may seem to be a paradox that inflammatory markers increase in 
neutropenic patients. With fewer leucocytes to produce the inflammatory markers, the 
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measured levels should be low. But the true biological reality may be different. There 
are many cell types not belonging to the hematological cells that produce 
inflammatory markers. In fact, almost all cell types in the body possess the property 
to produce inflammatory markers. One example are epithelial cells, especially the 
lining cells of the gastrointestinal tract [Sharma, et al., 2010], and the endothelial cells 
of the vasculature. Fibroblasts [Kato-Kogoe, et al., 2010], dendritic cells, Kuppfer 
cells in the liver, Sertoli cells of the testes, and melanocytes are other examples of 
cells that produce inflammatory markers [personal communication, Pål Aukrust, Oslo 
University Hospital, June 2012]. 
   Sixty of the 61 patients survived through day 30 after randomization. The one 
patient, mentioned before, with a reduced level of MBL (326 μg/L), unfortunately died 
29 days after randomization. During her HDT, all blood cultures and other 
microbiological tests were negative. She felt well and was in her normal state of 
health when she was discharged to home only eight days after randomization. 
Twelve days later she noticed fever and cough. The condition quickly deteriorated. 
Eight days later she was intubated and transferred to the regional medical center with 
a clinical picture of adult respiratory distress syndrome. She expired the next day. A 
post-mortem examination did not reveal any microbiological organisms as the cause 
of her fatal outcome. However, she had received broad-spectrum antibiotics. We do 
not know if the decreased MBL values that were found in her case contributed to the 
rapidly fatal course she experienced; still, this cannot be ruled out. 
   Several studies point at an increase in the risk of different serious infections in 
immunocompromised hosts with deficient or decreased MBL levels [Dommett, et al., 
2006; and Peterslund, et al., 2001]. The role of MBL in the innate immune response 
still needs elucidation; however, opsonization impairment and defects in the 
complement response are probably among the major mechanisms involved, when 
reduced levels of MBL occur together with other immunodeficiencies like status after 
anti-cancer chemotherapy [Dommett, et al., 2006]. 
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5.2 Aminoglycosides: synergy and antimicrobial resistance 
   The synergy between an aminoglycoside and a cell wall active antimicrobial agent 
is a desirable interaction that has several implications. The mechanism of the 
aminoglycoside’s synergistic activity with other antimicrobial agents may not be the 
same for all target organisms. Still, increased uptake of the aminoglycoside in the 
presence of a cell wall active agent seems to be important, at least for the action 
against enterococci, viridans streptococci, Staphylococcus aureus, and P. aeruginosa 
[Gilbert and Leggett, 2010]. 
   The positively charged cationic aminoglycosides bind both to the negatively 
charged RNA backbone of the ribosomes, to the Gram-negative cell wall 
lipopolysaccarides (LPS), to the cell membrane phospholipids, and to other anionic 
molecules. For example, cationic aminoglycosides interact chemically with anionic ȕ-
lactam antibiotics with mutual loss of antibacterial activity. This reaction is not very 
rapid. It occurs molecule to molecule, and it requires several hours to be of 
importance. Because of the 40-fold difference in serum concentrations, there is no 
important reduction in the ȕ-lactam concentration. However, there may be a  
10 – 20 % reduction in the aminoglycoside serum concentration. Therefore, the 
recommendation in Mandell’s textbook is that the aminoglycoside should always be 
administered first [Gilbert and Leggett, 2010].  
   Aminoglycosides work fast and it is the initial peak serum concentration that is 
important. This knowledge may not be adequately appreciated. The third EORTC trial 
[Klastersky, et al., 1986] stated explicitly, for unknown reasons, that the ȕ-lactam 
should be administered before the aminoglycoside. Neither were we aware of this 
phenomenon; the protocol of The Tobramycin Trial (Paper 2) did not specify the 
sequence of administration of the aminoglycoside and the penicillin G.  
   A telephone survey to 22 Norwegian departments of hematology, oncology and 
infectious diseases in March 2012 revealed that no department had guidelines for the 
sequence of administration of aminoglycosides and cell-wall active antibiotics. In 
general, this was left to the discretion of the nurses. Twelve departments reported 
that they usually gave the penicillin G first, mainly because that was easier and more 
convenient. One department simply stated that no guideline existed. Seven 
departments stated that they gave the aminoglycoside first. One reason given for this 
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practice was that it was more important to give the anti-Gram-negative drug as soon 
as possible. Two departments at regional medical centers reported that they did not 
use the combination of aminoglycoside plus penicillin G at all. 
   There may seem to be a contradiction here. On one side, the presence of the cell-
wall active drug appears to improve the uptake of the aminoglycoside into the 
bacterial cytoplasm. On the other side, the aminoglycoside should be given first to 
prevent the reduction in aminoglycoside serum concentration by the mutual 
inactivation of the cationic aminoglycoside and the anionic ȕ-lactam. Which is more 
important? Aminoglycosides do have an immediate action when it binds to all anionic 
molecules on and in the bacterium and in its environment, including the 
lipopolysaccaride (endotoxin) in the bacterial Gram-negative outer membrane, 
causing a rearrangement of these molecules with a subsequent “bleeding” of the 
outer membrane, with formation of transient holes in the cell wall that starts the killing 
of the bacterium and allows the aminoglycoside to enter the microbe’s inner part. 
One example of this is that empirical monotherapy with an aminoglycoside in urinary 
tract infections in most cases is the most effective therapy that may be given for this 
condition with urinary concentrations of the aminoglycoside being 25 to 100 times 
higher than the corresponding serum concentration [Gilbert and Leggett, 2010]. The 
ȕ-lactam thus is not mandatory in the initial phase of the aminoglycoside attack, even 
though the ȕ-lactam would help the aminoglycoside to enter the cell. But also, the 
high serum concentration of the aminoglycoside, when given once daily, would in 
most cases be high enough that eventual inactivation would be without clinical 
significance. Being aware of these two principles should make an individual 
evaluation possible when the bacterial MIC toward the aminoglycoside is known. 
Otherwise, the advice should be to follow the recommendation from Mandell’s 
textbook [Gilbert and Leggett, 2010] to give the aminoglycoside first. 
   Binding of aminoglycosides to prokaryotic ribosomes is a prerequisite for the drug’s 
antimicrobial activity. But, the exact mechanism of the cidal activity remains 
somewhat unclear. Recent work suggests that only bactericidal drugs stimulate 
hydroxyl radical formation in bacteria [Kohansky, et al., 2007], whatever their 
antibacterial mechanism may otherwise be. 
 
   To understand how the aminoglycoside antibiotics work, and the mechanisms of 
resistance to aminoglycosides, some further basic in-depth presentation is 
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necessary. Aminoglycosides bind with high avidity to a region of highly conserved 
nucleotides in the mRNA decoding region of the 30S subunit of prokaryotic 
ribosomes. The critical translation of the mRNA codon and anticodon of the 
aminoacyl-transfer RNA occurs at the A (acceptance) site in the 16S reverse transfer 
RNA portion of the 30S ribosomal subunit, where two adenine residues are inhibited 
by aminoglycoside interference. This leads to misreading of the mRNA and 
effectively stops the polypeptide production [Gilbert and Leggett, 2010].    
   This mechanism is a key to understanding the differential aminoglycoside effects 
on prokaryotic and eukaryotic cells; and also one of the bacterial resistance 
mechanisms toward aminoglycosides. In eukaryotic cells, the corresponding 
aminoglycoside binding site carries a guanosine instead of the prokaryotic 
adenosine, making eukaryotic ribosomes almost completely resistant to the effect of 
aminoglycosides, even though interesting research may prove aminoglycosides 
useful in therapy of selected genetic human diseases [Gilbert and Leggett, 2010].  
   Methylating enzymes that modify the 16S rRNA binding site result in high-level 
aminoglycoside resistance; this mechanism seems to be growing in clinical isolates 
worldwide. However, the most common mechanism of bacterial aminoglycoside 
resistance consists of three different aminoglycoside-modifying enzymes that all 
result in poor ribosome binding, and a high level of resistance [Shaw, et al., 1993]. 
The genes for these modifying enzymes can be spread by plasmids, sometimes in 
combination with other resistance genes on mobile genetic elements [Lindemann, et
al., 2012], but they may also be chromosomal. For unknown reasons, aminoglycoside 
resistance seems to be a smaller problem compared to ȕ-lactam and fluoroquinolone 
resistance in Northern Europe; even though Gram-negative aminoglycoside 
resistance may reach 60 - 70 % of the clinical isolates in certain parts of the world  
[Peripi, et al., 2012]. The low frequency of aminoglycoside resistance in our part of 
the world may be an effect of more appropriate and restricted use of 
aminoglycosides. However, aminoglycoside resistance also threatens to become a 
problem in Norway [NORM/NORMVET, 2011; Haldorsen, et al., 2011; and 
Lindemann, et al., 2012]. 
   Are there any new aminoglycosides with reduced resistance pattern in the pipeline? 
Amikacin was used in the last three of the four EORTC trials because there was a 
problem with increasing gentamicin resistance since the first EORTC trial. Since 
then, amikacin has been the aminoglycoside of choice in many countries. Norway is 
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one of the few countries where amikacin has not been available; and we have had 
few problems with gentamicin and tobramycin resistance. If aminoglycoside 
resistance should become more prevalent, amikacin might still be an option, and it is 
available in Sweden (Biklin® from Bristol-Myers-Squibb; “registreringsfritak” in 
Norway). Moreover, the second-generation aminoglycoside plazomicin, currently 
being evaluated in a phase II trial, is resistant to the aminoglycoside-modifying 
enzymes. However, it has no clinical effect against bacteria with the 16S rRNA 
binding site methylating enzymes [Zhanel, et al., 2012].     
   Low-level aminoglycoside resistance may occur secondarily to drug efflux 
mechanisms, causing the so-called adaptive resistance. This is a phenomenon 
described as a transient resistance, occurring after a treatment with an 
aminoglycoside, when the peak concentration only reaches a moderate value, for 
example secondary to dosing three times daily. Adaptive resistance follows the rapid, 
early concentration-dependent killing of susceptible bacteria, and lasts beyond the 
postantibiotic effective period into the time of regrowth. However, this effect lasts only 
a few hours. It may be an explanation for our results with higher concentrations of the 
proinflammatory markers (Paper 3) when the aminoglycoside was dosed once daily; 
by the hypothetical explanation, that higher number of living bacterial cells on the 
mucosa of the gastrointestinal tract secondary to lower serum aminoglycoside 
concentration with dosing three times daily, prevented the increase in the 
proinflammatory response. This hypothesis is based on the adaptive resistance that 
seems to disappear with the high serum peak concentrations of once daily dosing 
[Elisabeth von der Lippe, personal communication, 2011].  
   Aminoglycoside resistance is even more complex. Exposure of susceptible bacteria 
to aminoglycosides can select for two types of drug-resistant subpopulations. One is 
the phenomenon of adaptive resistance. The other results from small colony variants 
with deficient energy-dependent uptake of aminoglycosides, and may result in clinical 
treatment failure when the aminoglycoside has been used for a while [Gilbert and 
Leggett, 2010]. Initial aminoglycoside therapy is one of the most potent and rapidly 
working antibacterial treatments available. Prolonged therapy with aminoglycosides, 
on the other side, may cause clinical failures and unwanted side effects. A rule of 
thumb may be not to give aminoglycosides for more than eight to ten days if it is 
clinically possible. 
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5.3 Aminoglycosides and nephrotoxicity 
      An important question in aminoglycoside research and therapy has been whether 
once daily therapy versus multiple daily dosing has less renal side effects. We found 
only a minor increase in serum creatinine; equal in the two arms of our RCT study. 
Mavros and his co-workers [Mavros, et al., 2011] concluded that the occurrence of 
nephrotoxicity was similar between two dosing regimens of aminoglycosides, once 
daily or multiple daily doses,  based on seven RCTs with 1643 patient episodes  
(RR = 0.74; 95 % CI: 0.36 - 1.50), with a trend in favor of once daily dosing. 
   To understand the risk of severe aminoglycoside nephrotoxicity, studies from the 
1970s provide one perspective on this discussion. In studies conducted before the 
concentration-dependent pharmacodynamic mode of action of aminoglycosides was 
known [Craig, 1998], gentamicin was often administered four times daily with doses 
of 0.75 mg/kg in every dose. They aimed at peak serum concentrations of four mg/L 
[Bodey, et al., 1972; Bodey, et al., 1973; and Schimpff, et al., 1971].  
   In one study, gentamicin was even administered as a continuous infusion [Keating, 
et al., 1979], and gentamicin levels were sought kept at four to five mg/L. The 
patients received gentamicin for a minimum of seven days, or four days after 
becoming afebrile. Nephrotoxicity was described as azotemia, and major azotemia 
was defined as an increase in serum creatinine to above 2.5 mg/dL (191 μmol/L) or 
as an increase in serum BUN (urea) to above 50 mg/dL (18 mmol/L). Major azotemia 
occurred in 19 % of the patients who had serum concentrations of gentamicin above 
five mg/L. Minor azotemia “…was usually transient and of no clinical significance” 
[Keating, et al., 1979]. These results may suggest that the minor increases in serum 
creatinine that we found in The Tobramycin Trial were not of clinical significance. 
Moreover, aminoglycoside nephrotoxicity is reversible in most cases. The cells of the 
proximal renal tubules start regeneration already while the aminoglycoside 
administration is still being continued [Gilbert and Leggett, 2010]. 
   In our regular daily work with cancer patients, after The Tobramycin Trial, the 
question of who may safely receive aminoglycosides and who should be deferred 
from such therapy is important. We have decided not to use aminoglycosides in 
patients with multiple myeloma, to avoid causing severe nephrotoxicity in patients 
with myeloma renal disease, even though this is an unusual condition [Peters, et al., 
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2011]. We also avoid the use of aminoglycosides in patients who are planned to 
receive future nephrotoxic anti-cancer therapy, in particular cis-platinum. Several 
studies have documented a prolonged, maybe life-long, subclinical reduced renal 
function after therapy with cis-platinum, often suggested by a low serum magnesium 
level [Aass, et al., 1990; Fosså, et al., 2002]. In this situation, when the cancer is 
cured, starting therapy with penicillin G plus an aminoglycoside may be appropriate 
as long as their creatinine levels and other signs of nephrotoxicity are closely 
followed. 
 
5.4 Important developments in the last decade 
   Over the years, internationally and in Norway, Gram-positive coccal bacteremias 
became more prevalent in FN cancer patients. This probably happened as a 
consequence of more intensive anti-cancer chemotherapy, causing more mucositis, 
rendering the patients prone to invasion primarily by Į-hemolytic oral streptococci. 
The more widespread use of central venous accesses also rendered the patients 
susceptible to infections with S. aureus and even more to coagulase-negative 
staphylococci. The focus on methicillin-resistant S. aureus (MRSA) and other Gram-
positive cocci resistant to the available Gram-positive antibacterial agents, triggered 
the fifth EORTC trial in the 1980s and 90s, where the question was if empirical 
addition of vancomycin to the established antibiotic regimen would decrease the 
fatality rate in FN [EORTC, 1991]. The trial concluded that vancomycin should not be 
added to the initial empiric regimen, unless the local epidemiology showed a high 
rate of Gram-positive cocci resistant to the standard antibiotic regimen. 
   Ten years ago, the multiresistant Gram-positive cocci seemed to represent the 
major threat to the global antibacterial resistance situation. In Norway, the first 
vancomycin-resistant Enterococcus faecium was found in 1998 [Torfoss, et al., 
1999], and MRSA continued to increase for many years. In Norway, the total MRSA 
rate stabilized around 1 % of the reported S. aureus blood culture isolates 
[NORM/NORMVET, 2011].  
   However, the most recent developments show an important increase in cases of 
clinical MRSA in the capital region of Norway [Jørgensen, et al., 2012]. Since 2010, 
there has been a 34 % increase in MRSA cases. Fifteen local outbreaks in health 
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care institutions were reported in 2010 and 2011. In the worst case, this may be the 
beginning of an epidemic similar to what the United Kingdom experienced in the 
1990s, leading to an epidemic with > 40 % of the S. aureus isolates being MRSA 
during the course of a couple of years [Iversen, 2004]. This alarming situation may 
call for all available interventions with a possible effect. Combination chemotherapy, 
especially the combination of an aminoglycoside with a ȕ-lactam, may reduce the 
evolution of resistance [Gilbert and Leggett, 2010; Gerber, et al., 1982]. Important 
research showing benefit of antimicrobial combinations to reduce the emergence of 
resistance was done in the 1980s [Michea-Hamzehpour, et al., 1986; Pechere, et al., 
1986]. This may be another argument for the increased use of aminoglycosides in 
combination both with penicillin G and with other ȕ-lactams even though we really do 
not know if this measure may reduce the further evolution and spread of antibiotic 
resistance. In addition, strict attention to, and enforcement of, hospital infection 
control principles remain of utter importance. 
   Resistant Gram-positive cocci certainly remain a continuous problem. There has 
been an epidemic of vancomycin-resistant enterococci (VRE) that started in Bergen 
in 2010, and there has been another, so far smaller, VRE epidemic at Oslo University 
Hospital, at the Ullevål Hospital campus in 2011. A total of 391 cases of VRE have 
been reported from January 2010 until May 15th 2012 to “MSIS” (Meldesystem for 
smittsomme sykdommer, Norway) [FHI, 2012]. Most recently, in September 2012, 
another report of an outbreak of VRE at the main hospital in Fredrikstad has been 
reported. 
   A more virulent Clostridium difficile strain (0 27) [Vaishnavi C, 2011], causing 
increased case fatality rate has become a global problem, but so far only few cases 
have been reported in Norway. Widespread use of fluoroquinolones seems to be one 
important cause for this development. Fluoroquinolones have been an important 
class of antibiotics that regrettably is gradually loosing its antibacterial power by the 
rapid increase of resistance world wide. It is the only class of oral antibiotics, with a 
broad antibacterial spectrum against Gram-negative bacilli. Unfortunately, these 
synthetic antimicrobials are only very slowly metabolized in the nature; and the huge 
consumption of fluoroquinolones both in human medicine and as veterinary 
(especially aquacultural) growth promoters, probably will throw a long ecological 
shadow of constant promotion of microbial resistance. 
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   In the last decade, international resistance in Gram-negative bacteria has emerged 
as one of the major problems in antibiotic therapy in severe infections. Norway has 
also had many local outbreaks of strains with extended-spectrum-ȕ-lactamases 
(ESBL) in Gram-negative bacilli [NORM/NORMVET, 2011; Haldorsen, 2011; and 
Lindemann, et al., 2012]. Recently, the first E. coli strain containing a New Dehli 
Metallocarbapenemase - 1 (NDM - 1) was isolated in Norway [Haldorsen, 2011]. 
Similar situations are frequently reported in other countries [Kumarasamy, et al., 
2010; Nemec and Krizova, 2012; Livermore, 2012]. The total global antibiotic 
resistance situation seems to be increasing, and Gram-negative resistance may be 
the major threat at the moment. But as we have seen, Gram-positive resistance also 
seems to be increasing. In the worst case, this may take us back into the situation we 
had before penicillin was discovered by Alexander Fleming in 1928 and put into 
medical use in the 1940s. 
    
   Based on important research, the epidemiology of FN again came into focus at the 
turn of the century. FN patients constitute a heterogeneous group of patients. 
Algorithms have been developed to identify patients with low risk for complications 
and fatal outcomes. The trial by the Multinational Association for Supportive Care in 
Cancer (MASCC) has established an algorithm which makes it possible to identify 
patients with low risk for complications based on a few immediately available clinical 
parameters [Klastersky, et al., 2000]. This algorithm opens for safe treatment of FN 
patients with low risk for complications with oral antibiotics. Unfortunately, the oral 
regimen has to rely on the use of fluoroquinolones. Hand in hand with this 
development, hospitals have built patient hotels, both improving the quality of life of 
FN patients, and reducing the cost of care for these patients. 
 
   Other important events relating to FN during the last decade has been the 
substantial increase in new antifungal drugs [Nordøy and Gaustad, 2008]. Invasive 
fungal infections were frequently fatal a decade ago. These new drugs have to some 
extent changed the poor prognosis of invasive fungal infections. However, with more 
intensive and aggressive cancer therapy, more invasive fungal infections are likely to 
occur. A challenge with the new drugs is the tendency to overuse them, resulting in 
development of antifungal resistance [Nordøy and Gaustad, 2008]. 
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   In Norway, we have tried to prevent unnecessary use of both antibacterial and 
antifungal drugs to reduce the spread of antimicrobial resistance. Antifungal 
prophylaxis is seldom used. Candida albicans is still the most common clinical 
candida isolate in Norwegian hospitals; and C. albicans has remained sensitive to 
fluconazole [Sandven, et al., 2006; Gammelsrud, et al., 2011]. In Norway, 
recommendations against prophylactic use of antibiotics and antifungal drugs are 
common [Torfoss and Høiby, 2010; Simonsen, 2010]. Reported case fatality in initial 
FN is very low, and systemic fungal infections are rare [Torfoss and Sandven, 2005]. 
 
   Prevention of FN complications by trying to avoid neutropenia, or to abate the 
seriousness and duration of neutropenia, has lead to systematic use of granulocyte 
growth factors (G-CSF). Patients with a risk of FN > 20 % should always get G-CSF 
along with the cancer chemotherapy treatment, and patients with a risk of FN 
between 10 and 20 % should receive G-CSF if they have additional risk factors like 
certain comorbidities (especially pulmonary comorbidities), age > 65 years and 
previous FN [Aapro, et al., 2011]. This is a strategy that reduces the occurrence and 
severity of FN; and thus reduces the consumption of antibiotics. Even though G-CSF 
has some unwanted side effects, the avoidance and the reduction in severity of FN 
are in general beneficial both to the patients and to the microbiological resistance 
epidemiology as well as the cost of antimicrobial chemotherapy. 
   The new 13-valent pneumococcal conjugate vaccine, a further evolution of the  
seven-valent pneumococcal conjugate vaccine, is probably one step forward 
regarding prophylaxis in immunocompromised patients [Vestrheim, et al., 2008]. 
Further progress for conjugated pneumococcal vaccines is probable. This vaccine, 
and the annual influenza vaccine, should in general be offered to cancer patients 
even though the effect of vaccination may sometimes be hampered by 
immunosuppression caused by drugs and the diseases [Brydak and Calbecka, 1999; 
Nordøy, et al., 2002; Yri, et al., 2011; de Lavallade et al., 2011]. In particular, patients 
with decreased or absent splenic function should be vaccinated against infections 
caused by bacteria with virulent capsules like pneumococci and Haemophilus
influenzae. 
 
   In Norway, as in most developed countries, governmental bodies have established 
programs to fight antibiotic resistance. The first program was launched at the turn of 
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the century, “Regjeringens tiltaksplan mot antibiotikaresistens 2000-2004” [Nyquist, 
et al., 2000], with follow-up programs that are currently in action, ”Nasjonal strategi 
for forebygging av infeksjoner i helsetjenesten og antibiotikaresistens, 2008-2012” 
[FHI, 2008]. 
   The medical microbiology and the medical infectious diseases specialists’ 
communities in Norway unanimously participate in this program. This thesis might 
also be seen as part of this program.  
   When The Tobramycin Trial was published in 2007, a plan for a follow-up trial 
comparing penicillin G plus an aminoglycoside with meropenem “Penicillin G and an 
aminoglycoside versus meropenem as initial, empiric therapy in lymphoma and 
leukemia patients with febrile neutropenia of expected long duration” had already 
started. It had been successful in recruiting 323 patients when it was completed and 
closed in October 2011. Hopefully, the first publication from this trial will be submitted 
at the end of 2012. 
   Two important organizations have been established during the last decade: first, a 
center dedicated to facilitate trials and prudent use of antibiotics in general practice, 
“The Antibiotic Centre for Primary Care”. In 2011, a center focusing on improving 
antibiotic use in hospitals was launched: “Nasjonalt kompetansesenter for 
antibiotikabruk i spesialisthelsetjenesten”.   
   Clinical studies of the specific Norwegian antibiotic policy, often restrictive and 
different from international guidelines, have, unfortunately, been a neglected area of 
research. Thanks to a few strong opinion-leaders among the Norwegian experienced 
infectious diseases faculty, the Norwegian antibiotic policy has been established and 
to a great extent followed by medical doctors in Norway; sometimes despite lack of 
scientific evidence. This situation will probably not continue into the future unless 
clinical trials are being conducted.  
   We do have an advantageous situation in Norway, both with regard to the 
antimicrobial epidemiology and the antibiotic consumption pattern. However, parts of 
the general and specialist antibiotic policy need to be evaluated or reevaluated, and 
parts of it need to be documented. The way the infectious diseases community and 
the medical microbiological community have organized themselves during the last 
decade, and the general tasks we work to complete, along with governmental 
support, has improved our chances to guard and to promote the goal of preventing 
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overwhelming antibiotic resistance in Norway, in spite of increased traveling, trade 
with food etc. 
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6. Conclusions and future perspectives 
 
   Penicillin G plus an aminoglycoside has been the standard, initial therapy in FN and 
in sepsis of unknown origin in Norway for decades, as confirmed by von der Lippe in 
2001 [von der Lippe, 2001]. As new broad-spectrum ȕ-lactams and fluoroquinolones 
were developed, Norwegian clinicians and authorities in general chose to continue 
the tradition of using penicillin G plus an aminoglycoside in severe and septic 
conditions. This has been an important strategic decision by the infectious diseases 
and the medical microbiological communities since the 1970s. This decision opposed 
the larger international infectious diseases communities, as well as the results of 
multiple RCTs, in general sponsored by the pharmaceutical industry; and pressure 
from the pharmaceutical industry. It is therefore surprising that almost no clinical RCT 
was initiated at that time in order to document the Norwegian antibiotic policy. Finally, 
it was primarily the Norwegian hematological and oncological communities that 
launched the initiative to document the efficacy and the safety of penicillin G plus an 
aminoglycoside in severe infections.  
   The fact that all the seven studies resulted in the same conclusion strengthens the 
evidence for our antibiotic policy. They all, and especially our RCT, concluded: 
penicillin G plus an aminoglycoside is effective and safe initial, empiric therapy in FN 
provided the regimen is modified if the clinical response is unsatisfactory. 
   However, with time, the microbiological epidemiology will change. This makes 
surveillance of results, and preferably follow-up antibiotic trials important quality 
measures for our continued antibiotic policy. 
   The reason why we insist on choosing the “old-fashioned” regimen of pencillin G 
plus an aminoglycoside, in our opinion, cannot be repeated often enough. This is the 
only broad-spectrum antibiotic combination that is likely to confer prevention against 
antibiotic resistance when a broad-spectrum antibiotic regimen is needed for a 
severe or a septic condition.  
   New antibiotic classes do not seem to come forward. Culture-free techniques for 
diagnosis and immunological or genetic methods for therapy of serious bacterial 
infections most likely cannot be expected within the near future [Berman, 2010]. 
Accordingly, all measures that reduce the problem of antibiotic resistance must be 
welcomed [Walsh, 2003].  
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   A promising event in 2011 was the article by the Editor of the Journal of 
Antimicrobial Chemotherapy, Dr. Leonard Leibovici with co-workers. Based on a 
discussion of ethical dilemmas in infectious diseases, they concluded with a strong 
support for an antibiotic policy based on the use of narrow-spectrum regimens in 
moderate to severe infections. They phrased this support as an ethical statement, 
that patients today must accept the possible risk of ”…less than maximum empirical 
antibiotic treatment in order to reduce the rise in resistance”, and that it must be done 
even ”…without the consent of the patient, disregarding the patient’s autonomy” 
[Leibovici, et al., 2011]. The authors concluded that ”…future patients have a right to 
come to no harm”, and ”…that the right of future patients to come to less harm 
outweighs the right of the present patient to share in decisions on antibiotic 
treatment.” This article, addressed to an international audience, gave credit to the 
anti-resistance focus of the Norwegian antibiotic policy. 
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Errata 
Page 17, line 26: “the three arm of the trial” should be substituted with “the three 
arms of the trial” 
Page 19 , line 8: “page 13” should be substituted with “page 17” 
Page 20, line 18: “ Gram-negatve bacilli” should be substituted with “Gram-negative 
bacilli” 
Page 51, line 8: “This mechanism is a key to understanding…” should be substituted 
with “This mechanism is a key to understand…” 
When printing the thesis an extra copyright page 2 was introduced. This has been 
corrected in the Table of contents. However, where an explanation of how to find a 
statement in the text is explained with a “see page so and so”, an extra page number 
should be added. For example, when discussing the results of Paper 2, page 36, 
referring to the patient who died 29 days after randomization, this is “further 
described in the Discussion, page 47 + 1 = 48)” 
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